



US009078658B2

(12) **United States Patent**  
**Hewitt et al.**

(10) **Patent No.:** **US 9,078,658 B2**  
(45) **Date of Patent:** **Jul. 14, 2015**

(54) **FILAMENTARY DEVICES FOR TREATMENT OF VASCULAR DEFECTS**

(71) Applicant: **SEQUENT MEDICAL INC.**, Aliso Viejo, CA (US)

(72) Inventors: **Todd J. Hewitt**, Laguna Niguel, CA (US); **Brian E. Merritt**, San Clemente, CA (US); **William R. Patterson**, Irvine, CA (US)

(73) Assignee: **SEQUENT MEDICAL, INC.**, Aliso Viejo, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/459,638**

(22) Filed: **Aug. 14, 2014**

(65) **Prior Publication Data**

US 2014/0358178 A1 Dec. 4, 2014

**Related U.S. Application Data**

(60) Provisional application No. 61/866,993, filed on Aug. 16, 2013.

(51) **Int. Cl.**

**A61M 29/00** (2006.01)

**A61B 17/12** (2006.01)

**A61B 17/00** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61B 17/12113** (2013.01); **A61B 17/12118** (2013.01); **A61B 17/12172** (2013.01); **A61B 2017/00867** (2013.01); **A61B 2017/1205** (2013.01); **A61B 2017/1209** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61B 17/12113**; **A61B 17/12172**; **A61B 2017/1205**

USPC ..... **606/151, 191, 200, 213; 623/1.1; 128/831**

See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

3,874,388 A 4/1975 King et al.  
4,282,875 A 8/1981 Serbinenko

(Continued)

**FOREIGN PATENT DOCUMENTS**

EP 0706876 4/1996  
EP 0808138 5/2005

(Continued)

**OTHER PUBLICATIONS**

A Complete Microcatheter Portfolio; A Broad Selection of Microcatheters. Boston Scientific Brochure 2007.

(Continued)

*Primary Examiner* — Julian W Woo


(74) *Attorney, Agent, or Firm* — O'Melveny & Myers

(57)

**ABSTRACT**

Devices and methods for treatment of a patient's vasculature with some embodiments configured for delivery with a microcatheter for treatment of the cerebral vasculature of a patient. Embodiments may include a self-expanding resilient permeable shell having a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together, which define a cavity of the permeable shell. Some embodiments may include at least about 40% composite filaments having a high strength material and a highly radiopaque material. In some embodiments, the total cross sectional area of the highly radiopaque material is between about 11% and about 30% of the total cross sectional area of the plurality of elongate elements.

**38 Claims, 31 Drawing Sheets**



(56)

## References Cited

## U.S. PATENT DOCUMENTS

4,346,712	A	8/1982	Handa et al.	6,391,037	B1	5/2002	Greenhalgh
4,402,319	A	9/1983	Handa et al.	6,425,914	B1	7/2002	Wallace et al.
4,619,246	A	10/1986	Molgaard Nielsen	6,428,558	B1	8/2002	Jones et al.
4,675,361	A	6/1987	Ward	6,447,531	B1	9/2002	Amplatz
4,729,278	A	3/1988	Graeff	6,454,780	B1	9/2002	Wallace
4,998,539	A	3/1991	Delsanti	6,461,370	B1	10/2002	Gray et al.
5,061,275	A	10/1991	Wallstén et al.	6,463,317	B1	10/2002	Kucharczyk
5,071,407	A	12/1991	Termin et al.	6,468,266	B1	10/2002	Bashiri et al.
5,108,407	A	4/1992	Geremia et al.	6,478,773	B1	11/2002	Gandhi et al.
5,122,136	A	6/1992	Guglielmi et al.	6,500,149	B2	12/2002	Gandhi et al.
5,154,705	A	10/1992	Fleischhacker et al.	6,506,204	B2	1/2003	Mazzocchi
5,158,545	A	10/1992	Trudell et al.	6,511,468	B1	1/2003	Cragg et al.
5,165,421	A	11/1992	Fleischhacker et al.	6,551,303	B1	4/2003	Van Tassel et al.
5,263,963	A	11/1993	Garrison	6,579,303	B2	6/2003	Amplatz
5,334,210	A	8/1994	Gianturco	6,585,748	B1	7/2003	Jeffree
5,378,239	A	1/1995	Termin	6,589,256	B2	7/2003	Forber
5,536,247	A	7/1996	Thornton	6,589,265	B1	7/2003	Palmer et al.
5,569,245	A	10/1996	Guglielmi et al.	6,599,308	B2	7/2003	Amplatz
5,578,074	A	11/1996	Mirigian	6,605,102	B1	8/2003	Mazzocchi et al.
5,591,222	A	1/1997	Susawa et al.	6,605,111	B2	8/2003	Bose et al.
5,601,595	A	2/1997	Smith	6,607,539	B1	8/2003	Hayashi et al.
5,630,840	A	5/1997	Mayer	6,613,074	B1	9/2003	Mittelberg
5,645,559	A	7/1997	Hachtman et al.	6,632,241	B1	10/2003	Hancock
5,725,552	A	3/1998	Kotula	6,635,068	B1	10/2003	Dubrul et al.
5,725,570	A	3/1998	Heath	6,638,257	B2	10/2003	Amplatz
5,733,294	A	3/1998	Forber	6,652,556	B1	11/2003	Van Tassel et al.
5,749,883	A	5/1998	Halpern	6,666,882	B1	12/2003	Bose et al.
5,759,161	A	6/1998	Ogawa	6,669,721	B1	12/2003	Bose et al.
5,766,219	A *	6/1998	Horton ..... 606/191	6,682,546	B2	1/2004	Amplatz
5,846,261	A	12/1998	Kotula et al.	6,689,150	B1	2/2004	Van Tassel
5,873,907	A	2/1999	Frantzen	6,689,486	B2	2/2004	Ho et al.
5,907,893	A	6/1999	Zadno-Azizi	6,719,778	B1	4/2004	Van Tassel et al.
5,916,235	A	6/1999	Guglielmi	6,730,119	B1	5/2004	Smalling
5,925,060	A	7/1999	Forber	6,743,236	B2	6/2004	Barry et al.
5,927,345	A	7/1999	Samson	6,743,251	B1	6/2004	Eder
5,928,260	A	7/1999	Chin et al.	6,746,468	B1	6/2004	Sepetka et al.
5,935,148	A	8/1999	Villar et al.	6,746,890	B2	6/2004	Gupta et al.
5,944,733	A	8/1999	Engelson	6,752,826	B2	6/2004	Holloway et al.
5,944,738	A	8/1999	Amplatz	6,780,196	B2	8/2004	Chin et al.
5,951,599	A	9/1999	McCrary	6,811,560	B2	11/2004	Jones et al.
5,964,797	A	10/1999	Ho	6,855,153	B2	2/2005	Saad
5,980,554	A	11/1999	Lenker et al.	6,855,154	B2	2/2005	Abdel-Gawwad
5,984,929	A	11/1999	Bashiri et al.	6,878,384	B2	4/2005	Cruise et al.
5,989,242	A	11/1999	Saadat et al.	6,936,055	B1	8/2005	Ken et al.
6,033,423	A	3/2000	Ken et al.	6,940,209	B2	9/2005	Henderson
6,063,070	A	5/2000	Eder	6,953,472	B2	10/2005	Palmer et al.
6,063,104	A	5/2000	Villar et al.	6,953,473	B2	10/2005	Porter
6,086,577	A	7/2000	Ken et al.	6,966,892	B2	11/2005	Gandhi et al.
6,093,199	A	7/2000	Brown et al.	6,994,092	B2	2/2006	van der Berg et al.
6,123,715	A	9/2000	Amplatz	7,001,409	B2	2/2006	Amplatz
6,139,564	A	10/2000	Teoh et al.	7,004,962	B2	2/2006	Stinson
6,142,975	A	11/2000	Jalisi et al.	7,011,671	B2	3/2006	Welch
6,152,144	A	11/2000	Lesh et al.	7,044,958	B2	5/2006	Douk et al.
6,156,061	A	12/2000	Wallace et al.	7,052,513	B2	5/2006	Thompson
6,159,206	A	12/2000	Ogawa	7,083,632	B2	8/2006	Avellanet et al.
6,168,615	B1	1/2001	Ken et al.	7,101,390	B2	9/2006	Nelson
6,168,618	B1	1/2001	Frantzen	7,122,043	B2	10/2006	Greenhalgh et al.
6,168,622	B1	1/2001	Mazzocchi	7,128,736	B1	10/2006	Abrams et al.
6,190,402	B1	2/2001	Horton et al.	7,179,276	B2	2/2007	Barry et al.
6,193,708	B1	2/2001	Ken et al.	7,182,774	B2	2/2007	Barry et al.
6,203,779	B1	3/2001	Ricci et al.	7,195,636	B2	3/2007	Avellanet et al.
6,221,086	B1	4/2001	Forber	7,198,613	B2	4/2007	Gandhi et al.
6,277,126	B1	8/2001	Barry et al.	7,201,918	B2	4/2007	Cruise
6,290,721	B1	9/2001	Heath	7,229,454	B2	6/2007	Tran
6,315,709	B1	11/2001	Garibaldi et al.	7,229,461	B2	6/2007	Chin et al.
6,325,815	B1	12/2001	Kusleika	7,275,471	B2	10/2007	Nishri et al.
6,342,068	B1	1/2002	Thompson	7,326,225	B2	2/2008	Ferrera et al.
6,344,048	B1	2/2002	Chin et al.	7,329,279	B2	2/2008	Haug et al.
6,346,117	B1	2/2002	Greenhalgh	7,331,980	B2	2/2008	Dubrul
6,350,270	B1	2/2002	Roue	7,410,482	B2	8/2008	Murphy
6,368,338	B1	4/2002	Konya	7,419,503	B2	9/2008	Pulnev et al.
6,368,339	B1	4/2002	Amplatz	7,569,066	B2	8/2009	Gerberding
6,375,668	B1	4/2002	Gifford et al.	7,573,382	B2	8/2009	Choubey et al.
6,375,670	B1	4/2002	Greenhalgh	7,575,582	B2	8/2009	Gandhi et al.
6,383,174	B1	5/2002	Eder	7,578,826	B2	8/2009	Gandhi et al.
				7,597,704	B2	10/2009	Frazier et al.
				7,648,532	B2	1/2010	Greenhalgh et al.
				7,695,488	B2	4/2010	Berenstein
				7,722,637	B2	5/2010	Barry et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,806,919	B2	10/2010	Bloom et al.	2007/0255388	A1	11/2007	Rudakov et al.
7,862,577	B2	1/2011	Gray et al.	2007/0265656	A1	11/2007	Amplatz et al.
7,942,925	B2	5/2011	Yodaf	2007/0288083	A1	12/2007	Hines
8,043,329	B2	10/2011	Khairkhahan	2008/0033341	A1	2/2008	Grad
8,142,456	B2	3/2012	Rosqueta et al.	2008/0119886	A1	5/2008	Greenhalgh et al.
8,182,506	B2	5/2012	Fitz et al.	2008/0195139	A1	8/2008	Donald et al.
8,192,480	B2	6/2012	Tieu et al.	2008/0200945	A1	8/2008	Amplatz et al.
8,313,505	B2	11/2012	Amplatz et al.	2008/0221600	A1	9/2008	Dieck et al.
8,398,670	B2	3/2013	Amplatz	2009/0025820	A1	1/2009	Adams
8,430,012	B1	4/2013	Marchand	2009/0062834	A1	3/2009	Moftakhar
8,551,132	B2	10/2013	Eskridge et al.	2009/0062841	A1	3/2009	Amplatz et al.
8,728,117	B1	5/2014	Janardhan et al.	2009/0082803	A1	3/2009	Adams et al.
2001/0031981	A1	10/2001	Evans et al.	2009/0112305	A1	4/2009	Goldmann et al.
2002/0065552	A1	5/2002	Jayaraman et al.	2009/0132024	A1	5/2009	Berkhoff
2002/0103542	A1	8/2002	Bilbo	2009/0227976	A1	9/2009	Calabria
2002/0143349	A1	10/2002	Gifford, III et al.	2009/0275974	A1	11/2009	Marchand
2002/0143361	A1	10/2002	Douk et al.	2009/0287291	A1	11/2009	Becking et al.
2002/0187288	A1	12/2002	Lim et al.	2009/0287294	A1	11/2009	Rosqueta et al.
2003/0012816	A1	1/2003	West et al.	2009/0318948	A1	12/2009	Linder et al.
2003/0171739	A1	9/2003	Murphy et al.	2010/0023048	A1	1/2010	Mach
2003/0181942	A1	9/2003	Sutton et al.	2010/0069948	A1	3/2010	Veznedaroglu
2003/0187473	A1	10/2003	Berenstein et al.	2010/0094409	A1	4/2010	Barker et al.
2003/0199913	A1	10/2003	Dubrul et al.	2010/0106235	A1	4/2010	Kariniemi et al.
2004/0059370	A1	3/2004	Greene et al.	2011/0022149	A1	1/2011	Cox
2004/0098027	A1	5/2004	Teoh et al.	2011/0046658	A1	2/2011	Connor et al.
2004/0111147	A1	6/2004	Rabkin et al.	2011/0054515	A1	3/2011	Bridgeman
2004/0122367	A1	6/2004	Sculati	2011/0152993	A1	6/2011	Marchand
2004/0143239	A1	7/2004	Zhou et al.	2011/0208227	A1	8/2011	Becking
2004/0158311	A1	8/2004	Berhow	2011/0208233	A1	8/2011	McGuckin
2004/0172053	A1	9/2004	Barry et al.	2011/0319926	A1	12/2011	Becking
2004/0186562	A1	9/2004	Cox	2012/0165919	A1	6/2012	Cox
2004/0193206	A1	9/2004	Gerberding et al.	2012/0197283	A1*	8/2012	Marchand et al. .... 606/191
2004/0193208	A1	9/2004	Talpade et al.	2012/0283768	A1	11/2012	Cox
2004/0220563	A1	11/2004	Eder	2013/0116722	A1	5/2013	Aboytes et al.
2004/0260333	A1	12/2004	Dubrul et al.	2013/0123830	A1	5/2013	Becking et al.
2005/0021075	A1	1/2005	Bonnette et al.	2013/0245667	A1	9/2013	Marchand et al.
2005/0033408	A1	2/2005	Jones et al.	2013/0274862	A1	10/2013	Cox et al.
2005/0053782	A1	3/2005	Sen et al.	2013/0274863	A1	10/2013	Cox et al.
2005/0096728	A1	5/2005	Ramer	2013/0274866	A1	10/2013	Cox et al.
2005/0112349	A1	5/2005	Laurencin et al.	2013/0274868	A1	10/2013	Cox et al.
2005/0113868	A1	5/2005	Devellian et al.	2014/0005714	A1*	1/2014	Quick et al. .... 606/200
2005/0119684	A1	6/2005	Guterman et al.	2014/0052233	A1	2/2014	Cox et al.
2005/0133046	A1	6/2005	Becker et al.	2014/0135734	A1	5/2014	Dakin et al.
2005/0149173	A1	7/2005	Hunter et al.				
2005/0216052	A1	9/2005	Mazzocchi et al.				
2005/0228434	A1	10/2005	Amplatz et al.				
2005/0267516	A1	12/2005	Soleimani et al.				
2006/0009798	A1	1/2006	Callister et al.				
2006/0009799	A1	1/2006	Kleshinski et al.				
2006/0052815	A1	3/2006	Fitz et al.				
2006/0052816	A1	3/2006	Bates et al.				
2006/0064151	A1	3/2006	Guterman et al.				
2006/0083721	A1	4/2006	Cohen et al.				
2006/0116708	A1	6/2006	Ogawa et al.				
2006/0155323	A1	7/2006	Porter et al.				
2006/0200192	A1	9/2006	Fitz et al.				
2006/0200234	A1	9/2006	Hines				
2006/0217799	A1	9/2006	Mailander et al.				
2006/0235464	A1	10/2006	Avellanet et al.				
2006/0247680	A1	11/2006	Amplatz et al.				
2006/0253149	A1	11/2006	Gandhi et al.				
2007/0021816	A1	1/2007	Rudin				
2007/0031584	A1	2/2007	Roth				
2007/0061006	A1	3/2007	Desatnik et al.				
2007/0088387	A1	4/2007	Eskridge et al.				
2007/0100419	A1	5/2007	Licata et al.				
2007/0106323	A1	5/2007	Barry et al.				
2007/0112380	A1	5/2007	Figulla				
2007/0142906	A1	6/2007	Figulla				
2007/0144124	A1	6/2007	Schewe et al.				
2007/0167911	A1	7/2007	Gandhi et al.				
2007/0173928	A1	7/2007	Morsi				
2007/0203062	A1	8/2007	Ellis-Behnke et al.				
2007/0208373	A1	9/2007	Zaver et al.				
2007/0225760	A1	9/2007	Moszner				

## FOREIGN PATENT DOCUMENTS

EP	1576929	9/2005
EP	1844717	10/2007
EP	1923019	5/2008
EP	2055263	6/2009
EP	2258275	12/2011
JP	52141092	11/1977
JP	H4-47415	4/1992
WO	WO 96/01591	1/1996
WO	WO 97/26939	7/1997
WO	WO 99/03404	1/1999
WO	WO 99/05977	2/1999
WO	WO 99/62432	12/1999
WO	WO 01/45571	6/2001
WO	WO 01/93782	12/2001
WO	WO 02/00139	1/2002
WO	WO 03/011151	2/2003
WO	WO 03/032818	2/2003
WO	WO 03/063732	8/2003
WO	WO 2004/047649	6/2004
WO	WO 2004/093742	11/2004
WO	WO 2005/117718	12/2005
WO	WO 2006/026744	3/2006
WO	WO 2006/055683	5/2006
WO	WO 2007/096183	8/2007
WO	WO 2008/151204	12/2008
WO	WO 2009/121006	1/2009
WO	WO 2009/036219	3/2009
WO	WO 2009/126747	10/2009
WO	WO 2009/132045	10/2009
WO	WO 2009/134337	11/2009

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO	WO 2009/135166	11/2009
WO	WO 2010/134914	11/2010
WO	WO 2011/057002	5/2011

## OTHER PUBLICATIONS

Allen et al., "Micromachine Wedge Stepping Motor," pp. 1-6, Nov. 12-20, 1998 ASME International Mechanical Engineering Congress, Anaheim, CA.

Altes et al., "Creation of Saccular Aneurysms in the Rabbit: A model Suitable for Testing Endovascular Devices," American Roentgen Ray Society, Feb. 2000.

Ansari et al., "Thrombosis of a Fusiform Intracranial Aneurysm Induced by Overlapping Neuroform Stents: Case Report," *Neurosurgery*, E950-E951 vol. 60, No. 5, May 2007.

Atritech Press Release, Minneapolis, Jun. 18, 2007 "Atritech Announces Intellectual Property Acquisition, Transaction Establishes Company as leader in Left Atrial Appendage Market".

Duerig, "The use of superelasticity in Modern Medicine," *MRS Bulletin*, Feb. 2002, 101-104.

Grabenwoger et al., "Endothelialization of Biosynthetic vascular Prosthesis After Laser Perforation," *Ann Thorac Surg*, 1998;66:S110-S114.

Guidet Softip XF Guide Catheters Brochure, Boston Scientific Corporation 2004.

Gupta et al., "Nitinol Thin Film Three Dimensional Devices-Fabrication and Applications," From: SMST-2003: Proceedings of the International Conference on Shape Memory and Superelastic Technologies Published: 2004.

Hill et al., "Initial Results of the AMPLATZER Vascular Plug in the treatment of Congenital Heart Disease," Technology and Services, Business Briefing: US Cardiology 2004.

"HSS Tube," Fort Wayne Metals Bulletin, 2009.

Jeffrey et al., "The Porus, Guidewire-Directed, Detachable Aneurysm Liner: A New Concept in the Endovascular Treatment of Intracranial Aneurysms," *AJNR Am J Neuroradiol* 20:774-779, May 1999.

Kallmes et al., "A New Endoluminal, Flow-Disrupting Device for Treatment of Saccular Aneurysms," *Stroke*, Journal of the American Heart Association 2007; 38:1-7.

Konya et al., "Preliminary Results with a New vascular Basket Occluder in a Swine," From the Laboratory JVIR 1999; 10:1043-1049.

Kwon et al., "Preliminary Results of the Luna Aneurysm Embolization System in a Rabbit Model: A New Intracranial Aneurysm Occlusion Device," *AJNR Am J Neuroradiol*, pp. 1-7, Dec. 16, 2010.

Liu et al., "Review of Progress in Shape-Memory polymers," *Journal of Materials Chemistry*, 2007, 17, 1543-1558.

Major et al. "Life of Nitinol Drawn Filled Wires with Ag or Au core for Medicinal Application," *International Journal of Mechanics*, vol. 7, Issue 2, 2013, pp. 73-80.

Matinlinna et al., "An Introduction to Silanes and Their Clinical Applications in Dentistry," *The International Journal of Prosthodontics*, 155-164 vol. 17, No. 2, 2004.

Nakayama et al., "Development of Microporous Covered Stents: Geometrical Design of the Luminal Surface," *The International Journal of Artificial Organs* vol. 28, No. 6, 2005, 600-608.

Nishi et al., "Embolization of experimental aneurysms using a heparin-loaded stent graft with micropores," *Cardiovascular Radiation Medicine* 4 (2003) 29-33.

Nishi et al., "Occlusion of Experimental Aneurysms with Heparin-Loaded, Microporous Stent Grafts," *Neurosurgery* vol. 53, No. 6, Dec. 2003, 1397-1405.

Quynh et al., Electrospinning of Polymeric Nanofibers for Tissue Engineering Applications: A Review (*Tissue Engr* 2006; 12(5):1197-1211.

Salamat et al., "Experimental Evaluation of a New Transcatheter Vascular Embolization Device in the Swine Model," *J Vasc Interv Radiol*, 2002; 12:301-311.

Schmitz-Rode et al., "Self-expandable Spindle for Transcatheter Vascular Occlusion: In Vivo Experiments" *Radiology* (1993) 188:95-100.

Shaffer et al., "Engineering Characteristics of Drawn Filled Nitinol Tube" SMST-2003: Proceedings of the International Conference on Shape Memory and Superelastic Technologies (ASM International), Published 2004.

Turk et al., "Evaluation of the TriSpan Neck Bridge Device for the Treatment of Wide-Necked Aneurysms: An Experimental Study in Canines Editorial Comment: An Experimental Study in Canines," *Stroke*. 2001;32:492-497.

Zimmermann et al., "Patent Foramen Oval Closure With the SeptRx Device, Initial Experience with the First "In-Tunnel" Device," *JACC Cardiovascular Interventions* vol. 3, No. 9., 2010.

International Preliminary Report on Patentability mailed on: Dec. 17, 2009 for International Application No. PCT/US2008/065694 filed on Jun. 3, 2008 and published as: WO/2008/151204 on Dec. 11, 2008. International Search Report and Written Opinion mailed on: Oct. 31, 2008 for International Application No. PCT/US2008/065694 filed on Jun. 3, 2008.

International Preliminary Report on Patentability mailed on: Nov. 11, 2010 for International Application No. PCT/US2009/042592 filed on May 1, 2009 and published as: WO/2009/135166 on Nov. 5, 2009. International Search Report and Written Opinion mailed on: Nov. 26, 2009 for International Application No. PCT/US2009/042592 filed on May 1, 2009.

International Search Report and Written Opinion mailed on: Jul. 28, 2011 for International Application No. PCT/US2010/055494 filed on Nov. 4, 2010 and published as WO/2011/057002 on May 12, 2011.

Extended European Search Report dated Apr. 24, 2014 in European Patent Application No. EP 08770070 filed: Jun. 3, 2008.

Extended European Search Report dated: Jul. 30, 2014 in European Patent Application No. EP 10829110 filed: Nov. 4, 2010.

Fort Wayne Metals HHS Tube brochure, p. 28-29 (2009), Fort Wayne, Indiana, www.oldsite.fwmetals.com.

Major, S. and Hubalovsky, S., "Life of Nitinol Drawn Filled Wires with Ag or Au Core for Medical Application," *International Journal of Mechanics* 2(7):73-80 (2013).

Schaffer, J.E. and Gordon, R., "Engineering Characteristics of Drawn Filled Nitinol Tube," SMST-2003: Proceedings of the International Conference on Shape Memory and Superelastic Technologies (ASM International), p. 109-118 (2004).

Caroff, J. et al., "Woven Endobridge (WEB) Device for endovascular treatment of ruptured intracranial wide-neck aneurysms: a single-center experience," *Neuroradiology*, 56(9):755-761 (Sep. 2014).

Caroff, J. et al., "Role of C-Arm VasoCT in the Use of Endovascular WEB Flow Disruption in Intracranial Aneurysm Treatment," *AJNR Am. J. Neuroradiol.* 35(7):1353-1357 (Jul. 2014).

Colla, R. et al., "Treatment of Wide-Neck Basilar Tip Aneurysms Using the Web II Device," *The Neuroradiology Journal* 26(6):669-677 (Dec. 2013).

Ding, Y.H. et al., "The Woven EndoBridge: A New Aneurysm Occlusion Device," *AJNR Am. J. Neuroradiol.* 32:607-611 (Mar. 2011).

Fiorella, D. et al., "Interobserver variability in the assessment of aneurysm occlusion with the WEB aneurysm embolization system," *J. NeuroInterv. Surg.* Jul. 1, 2014, pii: neurintsurg-2014-011251. doi: 10.1136/neurintsurg-2014-011251 [Epub ahead of print].

Klisch, J. et al., "The Woven EndoBridge Cerebral Aneurysm Embolization Device (WEB II): initial clinical experience," *Neuroradiology* 53:599-607 (2011).

Lubicz, B. et al., "WEB Device for Endovascular Treatment of Wide-Neck Bifurcation Aneurysms," *AJNR Am. J. Neuroradiol.* 34(6):1209-1214 (Jun.-Jul. 2013).

Lubicz, B. et al., "WEB-DL Endovascular Treatment of Wide-Neck Bifurcation Aneurysms: Short- and Midterm Results in a European Study," *AJNR Am. J. Neuroradiol.* 35(3):432-438 (Mar. 2014). doi: 10.3174/ajnr.A3869. Epub Jan. 23, 2014.

Mine et al., "Intrasaccular flow-diversion for treatment of intracranial aneurysms: the Woven EndoBridge," *Expert Rev. Med. Devices* 11(3): 315-325 (May 2014). doi: 0.1586/17434440.2014.907741. Epub Apr. 2, 2014.

Papagiannaki, C. et al., "WEB Intrasaccular Flow Disruptor—Prospective, Multicenter Experience in 83 Patients with 85 Aneurysms,"

(56)

**References Cited**

## OTHER PUBLICATIONS

*AJNR Am. J. Neuroradiol.* 35(11):2106-2111 (Nov.-Dec. 2014). 35(11):2106-11. doi: 10.3174/ajnr.A4028. Epub Jul. 3, 2014.

Pierot, L. et al., "Intrasaccular Flow-Disruption Treatment of Intracranial Aneurysms: Preliminary Results of a Multicenter Clinical Study," *AJNR Am J Neuroradiol.* 33(7):1232-1238 (Aug. 2012). doi: 10.3174/ajnr.A3191. Epub Jun. 7, 2012.

Pierot, L. et al., "Endovascular WEB Flow Disruption in Middle Cerebral Artery Aneurysms: Preliminary Feasibility, Clinical, and Anatomical Results in a Multicenter Study," *Neurosurgery* 73(1):27-35 (Jul. 2013).

Pierot, L. et al., "Role, safety, and efficacy of WEB flow disruption: a review," *EJMINT* Invited Review, 2014: 1419000139 (May 8, 2014).



Peirot, L. et al., "WEB Treatment of Intracranial Aneurysms: Feasibility, Complications, and 1-Month Safety Results with the WEB DL and WEB SL/SLS in the French Observatory," *AJNR Am J Neuroradiol.* Feb. 5, 2015 [Epub ahead ofprint].


Simgen, A. et al., "Evaluation of a newly designed flow diverter for the treatment of intracranial aneurysms in an elastase-induced aneurysm model, in New Zealand white rabbits," *Neuroradiology* 56:129-137 (2014).


Spelle, L. and Liebig, T., "Letter to the Editor," *Neuroradiol J.* Jun. 2014; 27(3):369. doi: 10.15274/NRJ-2014-10048. Epub Jun. 17, 2014.

Wallner, A.K. et al., "Coiling after Treatment with the Woven EndoBridge Cerebral Aneurysm Embolization Device," *Interventional Neuroradiology* 18:208-212 (2012).


\* cited by examiner












*FIG. 5*








FIG. 9




FIG. 10




FIG. 11




FIG. 12






FIG. 13








FIG. 17




FIG. 18








FIG. 19











FIG. 27





FIG. 28






FIG. 29




FIG. 30






FIG. 31



*FIG. 32*



*FIG. 33*

FIG. 34





FIG. 35






FIG. 36




FIG. 37







FIG. 38







*FIG. 42*

FIG. 43











FIG. 46




*Distal portion of aneurysm with complete occlusion*



Pre-treatment Angiogram

FIG. 47



10 minutes Post treatment

FIG. 48

FIG. 49







FIG. 50



1

## FILAMENTARY DEVICES FOR TREATMENT OF VASCULAR DEFECTS

### RELATED PATENT APPLICATIONS

This patent application claims priority under 35 U.S.C. section 119(e) from U.S. Provisional Application No. 61/866, 993, filed Aug. 16, 2013, naming Todd J. Hewitt, Brian E. Merritt and Tan Q. Dinh as inventors, entitled FILAMENTARY DEVICES FOR TREATMENT OF VASCULAR DEFECTS, which is incorporated by reference herein in its entirety.

### FIELD OF THE INVENTION

Embodiments of devices and methods herein are directed to blocking a flow of fluid through a tubular vessel or into a small interior chamber of a saccular cavity or vascular defect within a mammalian body. More specifically, embodiments herein are directed to devices and methods for treatment of a vascular defect of a patient including some embodiments directed specifically to the treatment of cerebral aneurysms of patients.

### BACKGROUND

The mammalian circulatory system is comprised of a heart, which acts as a pump, and a system of blood vessels which transport the blood to various points in the body. Due to the force exerted by the flowing blood on the blood vessel the blood vessels may develop a variety of vascular defects. One common vascular defect known as an aneurysm results from the abnormal widening of the blood vessel. Typically, vascular aneurysms are formed as a result of the weakening of the wall of a blood vessel and subsequent ballooning and expansion of the vessel wall. If, for example, an aneurysm is present within an artery of the brain, and the aneurysm should burst with resulting cranial hemorrhaging, death could occur.

Surgical techniques for the treatment of cerebral aneurysms typically involve a craniotomy requiring creation of an opening in the skull of the patient through which the surgeon can insert instruments to operate directly on the patient's brain. For some surgical approaches, the brain must be retracted to expose the parent blood vessel from which the aneurysm arises. Once access to the aneurysm is gained, the surgeon places a clip across the neck of the aneurysm thereby preventing arterial blood from entering the aneurysm. Upon correct placement of the clip the aneurysm will be obliterated in a matter of minutes. Surgical techniques may be effective treatment for many aneurysms. Unfortunately, surgical techniques for treating these types of conditions include major invasive surgical procedures which often require extended periods of time under anesthesia involving high risk to the patient. Such procedures thus require that the patient be in generally good physical condition in order to be a candidate for such procedures.

Various alternative and less invasive procedures have been used to treat cerebral aneurysms without resorting to major surgery. Some such procedures involve the delivery of embolic or filling materials into an aneurysm. The delivery of such vaso-occlusion devices or materials may be used to promote hemostasis or fill an aneurysm cavity entirely. Vaso-occlusion devices may be placed within the vasculature of the human body, typically via a catheter, either to block the flow of blood through a vessel with an aneurysm through the formation of an embolus or to form such an embolus within an aneurysm stemming from the vessel. A variety of implantable, coil-type

2

vaso-occlusion devices are known. The coils of such devices may themselves be formed into a secondary coil shape, or any of a variety of more complex secondary shapes. Vaso-occlusive coils are commonly used to treat cerebral aneurysms but suffer from several limitations including poor packing density, compaction due to hydrodynamic pressure from blood flow, poor stability in wide-necked aneurysms and complexity and difficulty in the deployment thereof as most aneurysm treatments with this approach require the deployment of multiple coils.

Another approach to treating aneurysms without the need for invasive surgery involves the placement of sleeves or stents into the vessel and across the region where the aneurysm occurs. Such devices maintain blood flow through the vessel while reducing blood pressure applied to the interior of the aneurysm. Certain types of stents are expanded to the proper size by inflating a balloon catheter, referred to as balloon expandable stents, while other stents are designed to elastically expand in a self-expanding manner. Some stents are covered typically with a sleeve of polymeric material called a graft to form a stent-graft. Stents and stent-grafts are generally delivered to a preselected position adjacent a vascular defect through a delivery catheter. In the treatment of cerebral aneurysms, covered stents or stent-grafts have seen very limited use due to the likelihood of inadvertent occlusion of small perforator vessels that may be near the vascular defect being treated.

In addition, current uncovered stents are generally not sufficient as a stand-alone treatment. In order for stents to fit through the microcatheters used in small cerebral blood vessels, their density is usually reduced such that when expanded there is only a small amount of stent structure bridging the aneurysm neck. Thus, they do not block enough flow to cause clotting of the blood in the aneurysm and are thus generally used in combination with vaso-occlusive devices, such as the coils discussed above, to achieve aneurysm occlusion.

A number of aneurysm neck bridging devices with defect spanning portions or regions have been attempted, however, none of these devices have had a significant measure of clinical success or usage. A major limitation in their adoption and clinical usefulness is the inability to position the defect spanning portion to assure coverage of the neck. Existing stent delivery systems that are neurovascular compatible (i.e. deliverable through a microcatheter and highly flexible) do not have the necessary rotational positioning capability. Another limitation of many aneurysm bridging devices described in the prior art is the poor flexibility. Cerebral blood vessels are tortuous and a high degree of flexibility is required for effective delivery to most aneurysm locations in the brain.

What has been needed are devices and methods for delivery and use in small and tortuous blood vessels that can substantially block the flow of blood into an aneurysm, such as a cerebral aneurysm, with a decreased risk of inadvertent aneurysm rupture or blood vessel wall damage. In addition, what have been needed are devices that are easily visible with current imaging technology such as x-ray, fluoroscopy, magnetic resonance imaging and the like.

### SUMMARY

One embodiment of a device for treatment of a patient's vasculature includes a self-expanding resilient permeable shell having a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together, which define a cavity of

3

the permeable shell and which include at least about 40% composite filaments relative to a total number of filaments, the composite filaments including a high strength material and a highly radiopaque material.

One embodiment of a device for treatment of a patient's vasculature includes a self-expanding resilient permeable shell having a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together, the plurality of filaments having a total cross sectional area and further defining a cavity of the permeable shell and which include at least some composite filaments, the composite filaments including a high strength material and a highly radiopaque material, and wherein the total cross sectional area of the highly radiopaque material is between about 11% and about 30% of the total cross sectional area of the plurality of elongate filaments.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an elevation view of an embodiment of a device for treatment of a patient's vasculature and a plurality of arrows indicating inward radial force.

FIG. 2 is an elevation view of a beam supported by two simple supports and a plurality of arrows indicating force against the beam.

FIG. 3 is a bottom perspective view of an embodiment of a device for treatment of a patient's vasculature.

FIG. 4 is an elevation view of the device for treatment of a patient's vasculature of FIG. 3.

FIG. 5 is a transverse cross sectional view of the device of FIG. 4 taken along lines 5-5 in FIG. 4.

FIG. 6 shows the device of FIG. 4 in longitudinal section taken along lines 6-6 in FIG. 4.

FIG. 7 is an enlarged view of the woven filament structure taken from the encircled portion 7 shown in FIG. 5.

FIG. 8 is an enlarged view of the woven filament structure taken from the encircled portion 8 shown in FIG. 6.

FIG. 9 is a proximal end view of the device of FIG. 3.

FIG. 10 is a transverse sectional view of a proximal hub portion of the device in FIG. 6 indicated by lines 10-10 in FIG. 6.

FIG. 11 is an elevation view in partial section of a distal end of a delivery catheter with the device for treatment of a patient's vasculature of FIG. 3 disposed therein in a collapsed constrained state.

FIG. 12 is an elevation view of a distal portion of a delivery device or actuator showing some internal structure of the device.

FIG. 13 is an elevation view of the delivery device of FIG. 12 with the addition of some tubular elements over the internal structures.

FIG. 14 is an elevation view of the distal portion of the delivery device of FIG. 13 with an outer coil and marker in place.

FIG. 15 is an elevation view of a proximal portion of the delivery device.

FIG. 16 illustrates an embodiment of a filament configuration for a device for treatment of a patient's vasculature.

FIG. 17 is a schematic view of a patient being accessed by an introducer sheath, a microcatheter and a device for treatment of a patient's vasculature releasably secured to a distal end of a delivery device or actuator.

FIG. 18 is a sectional view of a terminal aneurysm.

FIG. 19 is a sectional view of an aneurysm.

4

FIG. 20 is a schematic view in section of an aneurysm showing perpendicular arrows which indicate interior nominal longitudinal and transverse dimensions of the aneurysm.

FIG. 21 is a schematic view in section of the aneurysm of FIG. 20 with a dashed outline of a device for treatment of a patient's vasculature in a relaxed unconstrained state that extends transversely outside of the walls of the aneurysm.

FIG. 22 is a schematic view in section of an outline of a device represented by the dashed line in FIG. 21 in a deployed and partially constrained state within the aneurysm.

FIGS. 23-26 show a deployment sequence of a device for treatment of a patient's vasculature.

FIG. 27 is an elevation view in partial section of an embodiment of a device for treatment of a patient's vasculature deployed within an aneurysm at a tilted angle.

FIG. 28 is an elevation view in partial section of an embodiment of a device for treatment of a patient's vasculature deployed within an irregularly shaped aneurysm.

FIG. 29 shows an elevation view in section of a device for treatment of a patient's vasculature deployed within a vascular defect aneurysm.

FIG. 30 shows a proximal perspective view of an embodiment of a device for treatment of a patient's vasculature with a sealing zone embodiment indicated by a set of dashed lines.

FIGS. 31-35 illustrate various different embodiments of braiding patterns that may be used for permeable shells of devices for treatment of a patient's vasculature.

FIG. 36 illustrates a device for treatment of a patient's vasculature that includes non-structural fibers in the permeable shell structure of the device.

FIG. 37 is an enlarged view of non-structural fibers woven into filaments of a permeable shell structure.

FIG. 38 is an elevation view of a mandrel used for manufacture of a braided tubular member for construction of an embodiment of a device for treatment of a patient's vasculature with the initiation of the braiding process shown.

FIG. 39 is an elevation view of a braiding process for a braided tubular member used for manufacture of a device.

FIG. 40 is an elevation view in partial section of an embodiment of a fixture for heat setting a braided tubular member for manufacture of a device for treatment of a patient's vasculature.

FIG. 41 is an elevation view in partial section of an embodiment of a fixture for heat setting a braided tubular member for manufacture of a device for treatment of a patient's vasculature.

FIG. 42 is an elevation view in section that illustrates a flow of blood within an aneurysm of a patient's vasculature.

FIG. 43 is an elevation view in partial section of an embodiment of a device for treatment of a patient's vasculature.

FIG. 44 is an elevation view in partial section of an embodiment of a device for treatment of a patient's vasculature.

FIG. 45 is an elevation view of an embodiment of a device for treatment of a patient's vasculature.

FIG. 46 is an elevation view in partial section of an embodiment of a device for treatment of a patient's vasculature.

FIG. 47 represents the image of an angiogram depicting an aneurysm prior to treatment.

FIG. 48 depicts the aneurysm of FIG. 47 ten (10) minutes post-treatment.

FIG. 49 is a perspective view in section of a composite filament embodiment.

FIG. 50 is an elevation view of an embodiment of a device for treatment of a patient's vasculature.

FIG. 51 is a perspective view of an embodiment of a mandrel for making the embodiment of FIG. 50.

5

FIG. 52 is a top view of the mandrel of FIG. 51 with filaments loaded for braiding.

#### DETAILED DESCRIPTION

Discussed herein are devices and methods for the treatment of vascular defects that are suitable for minimally invasive deployment within a patient's vasculature, and particularly, within the cerebral vasculature of a patient. For such embodiments to be safely and effectively delivered to a desired treatment site and effectively deployed, some device embodiments may be configured for collapse to a low profile constrained state with a transverse dimension suitable for delivery through an inner lumen of a microcatheter and deployment from a distal end thereof. Embodiments of these devices may also maintain a clinically effective configuration with sufficient mechanical integrity once deployed so as to withstand dynamic forces within a patient's vasculature over time that may otherwise result in compaction of a deployed device. It may also be desirable for some device embodiments to acutely occlude a vascular defect of a patient during the course of a procedure in order to provide more immediate feedback regarding success of the treatment to a treating physician.

It should be appreciated by those skilled in the art that unless otherwise stated, one or more of the features of the various embodiments may be used in other embodiments.

Some embodiments are particularly useful for the treatment of cerebral aneurysms by reconstructing a vascular wall so as to wholly or partially isolate a vascular defect from a patient's blood flow. Some embodiments may be configured to be deployed within a vascular defect to facilitate reconstruction, bridging of a vessel wall or both in order to treat the vascular defect. For some of these embodiments, a permeable shell of the device may be configured to anchor or fix the permeable shell in a clinically beneficial position. For some embodiments, the device may be disposed in whole or in part within the vascular defect in order to anchor or fix the device with respect to the vascular structure or defect. The permeable shell may be configured to span an opening, neck or other portion of a vascular defect in order to isolate the vascular defect, or a portion thereof, from the patient's nominal vascular system in order allow the defect to heal or to otherwise minimize the risk of the defect to the patient's health.

For some or all of the embodiments of devices for treatment of a patient's vasculature discussed herein, the permeable shell may be configured to allow some initial perfusion of blood through the permeable shell. The porosity of the permeable shell may be configured to sufficiently isolate the vascular defect so as to promote healing and isolation of the defect, but allow sufficient initial flow through the permeable shell so as to reduce or otherwise minimize the mechanical force exerted on the membrane the dynamic flow of blood or other fluids within the vasculature against the device. For some embodiments of devices for treatment of a patient's vasculature, only a portion of the permeable shell that spans the opening or neck of the vascular defect, sometimes referred to as a defect spanning portion, need be permeable and/or conducive to thrombus formation in a patient's bloodstream. For such embodiments, that portion of the device that does not span an opening or neck of the vascular defect may be substantially non-permeable or completely permeable with a pore or opening configuration that is too large to effectively promote thrombus formation.

In general, it may be desirable in some cases to use a hollow, thin walled device with a permeable shell of resilient material that may be constrained to a low profile for delivery

6

within a patient. Such a device may also be configured to expand radially outward upon removal of the constraint such that the shell of the device assumes a larger volume and fills or otherwise occludes a vascular defect within which it is deployed. The outward radial expansion of the shell may serve to engage some or all of an inner surface of the vascular defect whereby mechanical friction between an outer surface of the permeable shell of the device and the inside surface of the vascular defect effectively anchors the device within the vascular defect. Some embodiments of such a device may also be partially or wholly mechanically captured within a cavity of a vascular defect, particularly where the defect has a narrow neck portion with a larger interior volume. In order to achieve a low profile and volume for delivery and be capable of a high ratio of expansion by volume, some device embodiments include a matrix of woven or braided filaments that are coupled together by the interwoven structure so as to form a self-expanding permeable shell having a pore or opening pattern between couplings or intersections of the filaments that is substantially regularly spaced and stable, while still allowing for conformity and volumetric constraint.

As used herein, the terms woven and braided are used interchangeably to mean any form of interlacing of filaments to form a mesh structure. In the textile and other industries, these terms may have different or more specific meanings depending on the product or application such as whether an article is made in a sheet or cylindrical form. For purposes of the present disclosure, these terms are used interchangeably.

For some embodiments, three factors may be critical for a woven or braided wire occlusion device for treatment of a patient's vasculature that can achieve a desired clinical outcome in the endovascular treatment of cerebral aneurysms. We have found that for effective use in some applications, it may be desirable for the implant device to have sufficient radial stiffness for stability, limited pore size for near-complete acute (intra-procedural) occlusion and a collapsed profile which is small enough to allow insertion through an inner lumen of a microcatheter. A device with a radial stiffness below a certain threshold may be unstable and may be at higher risk of embolization in some cases. Larger pores between filament intersections in a braided or woven structure may not generate thrombus and occlude a vascular defect in an acute setting and thus may not give a treating physician or health professional such clinical feedback that the flow disruption will lead to a complete and lasting occlusion of the vascular defect being treated. Delivery of a device for treatment of a patient's vasculature through a standard microcatheter may be highly desirable to allow access through the tortuous cerebral vasculature in the manner that a treating physician is accustomed.

For some embodiments, it may be desirable to use filaments having two or more different diameters or transverse dimensions to form a permeable shell in order to produce a desired configuration as discussed in more detail below. The radial stiffness of a two-filament (two different diameters) woven device may be expressed as a function of the number of filaments and their diameters, as follows:

$$S_{radial} = (1.2 \times 10^6 \text{ lbf}/D^4) (N_l d_l^4 + N_s d_s^4)$$

where

$S_{radial}$  is the radial stiffness in pounds force (lbf),

$D$  is the Device diameter (transverse dimension),

$N_l$  is the number of large filaments,

$N_s$  is the number of small filaments,

$d_l$  is the diameter of the large filaments in inches, and

$d_s$  is the diameter of the small filaments in inches.

Using this expression, the radial stiffness,  $S_{radial}$  may be between about 0.014 and 0.284 lbf force for some embodiments of particular clinical value.

The maximum pore size in a portion of a device that spans a neck or opening of a vascular defect desirable for some useful embodiments of a woven wire device for treatment of a patient's vasculature may be expressed as a function of the total number of all filaments, filament diameter and the device diameter. The difference between filament sizes where two or more filament diameters or transverse dimensions are used, may be ignored in some cases for devices where the filament size(s) are very small compared to the device dimensions. For a two-filament device, the smallest filament diameter may be used for the calculation. Thus, the maximum pore size for such embodiments may be expressed as follows:

$$P_{max} = (1.7/N_T)(\pi D - (N_T d_w/2))$$

where

$P_{max}$  is the average pore size,

$D$  is the Device diameter (transverse dimension),

$N_T$  is the total number of all filaments, and

$d_w$  is the diameter of the filaments (smallest) in inches.

Using this expression, the maximum pore size,  $P_{max}$  of a portion of a device that spans an opening of a vascular defect or neck, or any other suitable portion of a device, may be less than about 0.016 inches or about 400 microns for some embodiments. In some embodiments the maximum pore size for a defect spanning portion or any other suitable portion of a device may be less than about 0.012 inches or about 300 microns.

The collapsed profile of a two-filament (profile having two different filament diameters) woven filament device may be expressed as the function:

$$P_c = 1.48((N_l d_l^2 + N_s d_s^2))^{1/2}$$

where

$P_c$  is the collapsed profile of the device,

$N_l$  is the number of large filaments,

$N_s$  is the number of small filaments,

$d_l$  is the diameter of the large filaments in inches, and

$d_s$  is the diameter of the small filaments in inches.

Using this expression, the collapsed profile  $P_c$  may be less than about 1.0 mm for some embodiments of particular clinical value. In some embodiments of particular clinical value, the device may be constructed so as to have all three factors ( $S_{radial}$ ,  $P_{max}$  and  $P_c$ ) above within the ranges discussed above;  $S_{radial}$  between about 0.014 lbf and 0.284 lbf,  $P_{max}$  less than about 300 microns and  $P_c$  less than about 1.0 mm, simultaneously. In some such embodiments, the device may be made to include about 70 filaments to about 300 filaments. In some cases, the filaments may have an outer transverse dimension or diameter of about 0.0004 inches to about 0.002 inches.

As has been discussed, some embodiments of devices for treatment of a patient's vasculature call for sizing the device which approximates (or with some over-sizing) the vascular site dimensions to fill the vascular site. One might assume that scaling of a device to larger dimensions and using larger filaments would suffice for such larger embodiments of a device. However, for the treatment of brain aneurysms, the diameter or profile of the radially collapsed device is limited by the catheter sizes that can be effectively navigated within the small, tortuous vessels of the brain. Further, as a device is made larger with a given or fixed number of resilient filaments having a given size or thickness, the pores or openings between junctions of the filaments are correspondingly larger. In addition, for a given filament size the flexural modulus or

stiffness of the filaments and thus the structure decrease with increasing device dimension. Flexural modulus may be defined as the ratio of stress to strain. Thus, a device may be considered to have a high flexural modulus or be stiff if the strain (deflection) is low under a given force. A stiff device may also be said to have low compliance.

To properly configure larger size devices for treatment of a patient's vasculature, it may be useful to model the force on a device when the device is deployed into a vascular site or defect, such as a blood vessel or aneurysm, that has a diameter or transverse dimension that is smaller than a nominal diameter or transverse dimension of the device in a relaxed unconstrained state. As discussed, it may be advisable to "over-size" the device in some cases so that there is a residual force between an outside surface of the device and an inside surface of the vascular wall. The inward radial force on a device **10** that results from over-sizing is illustrated schematically in FIG. **1** with the arrows **12** in the figure representing the inward radial force. As shown in FIG. **2**, these compressive forces on the filaments **14** of the device in FIG. **1** can be modeled as a simply supported beam **16** with a distributed load or force as shown by the arrows **18** in the figure. It can be seen from the equation below for the deflection of a beam with two simple supports **20** and a distributed load that the deflection is a function of the length,  $L$  to the 4<sup>th</sup> power:

$$\text{Deflection of Beam} = 5FL^4/384EI$$

where

$F$ =force,

$L$ =length of beam,

$E$ =Young's Modulus, and

$I$ =moment of inertia.

Thus, as the size of the device increases and  $L$  increases, the compliance increases substantially. Accordingly, an outward radial force exerted by an outside surface of the filaments **14** of the device **10** against a constraining force when inserted into a vascular site such as blood vessel or aneurysm is lower for a given amount of device compression or over-sizing. This force may be important in some applications to assure device stability and to reduce the risk of migration of the device and potential distal embolization.

In some embodiments, a combination of small and large filament sizes may be utilized to make a device with a desired radial compliance and yet have a collapsed profile which is configured to fit through an inner lumen of commonly used microcatheters. A device fabricated with even a small number of relatively large filaments **14** can provide reduced radial compliance (or increased stiffness) compared to a device made with all small filaments. Even a relatively small number of larger filaments may provide a substantial increase in bending stiffness due to change in the moment of Inertia that results from an increase in diameter without increasing the total cross sectional area of the filaments. The moment of inertia ( $I$ ) of a round wire or filament may be defined by the equation:

$$I = \pi d^4/64$$

where  $d$  is the diameter of the wire or filament.

Since the moment of inertia is a function of filament diameter to the fourth power, a small change in the diameter greatly increases the moment of inertia. Thus, a small change in filament size can have substantial impact on the deflection at a given load and thus the compliance of the device.

Thus, the stiffness can be increased by a significant amount without a large increase in the cross sectional area of a collapsed profile of the device **10**. This may be particularly important as device embodiments are made larger to treat



large aneurysms. While large cerebral aneurysms may be relatively rare, they present an important therapeutic challenge as some embolic devices currently available to physicians have relatively poor results compared to smaller aneurysms.

As such, some embodiments of devices for treatment of a patient's vasculature may be formed using a combination of filaments **14** with a number of different diameters such as 2, 3, 4, 5 or more different diameters or transverse dimensions. In device embodiments where filaments with two different diameters are used, some larger filament embodiments may have a transverse dimension of about 0.001 inches to about 0.004 inches and some small filament embodiments may have a transverse dimension or diameter of about 0.0004 inches and about 0.0015 inches, more specifically, about 0.0004 inches to about 0.001 inches. The ratio of the number of large filaments to the number of small filaments may be between about 2 and 12 and may also be between about 4 and 8. In some embodiments, the difference in diameter or transverse dimension between the larger and smaller filaments may be less than about 0.004 inches, more specifically, less than about 0.0035 inches, and even more specifically, less than about 0.002 inches.

As discussed above, device embodiments **10** for treatment of a patient's vasculature may include a plurality of wires, fibers, threads, tubes or other filamentary elements that form a structure that serves as a permeable shell. For some embodiments, a globular shape may be formed from such filaments by connecting or securing the ends of a tubular braided structure. For such embodiments, the density of a braided or woven structure may inherently increase at or near the ends where the wires or filaments **14** are brought together and decrease at or near a middle portion **30** disposed between a proximal end **32** and distal end **34** of the permeable shell **40**. For some embodiments, an end or any other suitable portion of a permeable shell **40** may be positioned in an opening or neck of a vascular defect such as an aneurysm for treatment. As such, a braided or woven filamentary device with a permeable shell may not require the addition of a separate defect spanning structure having properties different from that of a nominal portion of the permeable shell to achieve hemostasis and occlusion of the vascular defect. Such a filamentary device may be fabricated by braiding, weaving or other suitable filament fabrication techniques. Such device embodiments may be shape set into a variety of three dimensional shapes such as discussed herein. For example, any suitable braiding mechanism embodiment or braiding method embodiment such as those discussed in commonly owned U.S. Patent Publication No. 2013/0092013, published Apr. 18, 2013, titled "Braiding Mechanism and Methods of Use", which is incorporated by reference herein in its entirety, may be used to construct device embodiments disclosed herein.

Referring to FIGS. 3-10, an embodiment of a device for treatment of a patient's vasculature **10** is shown. The device **10** includes a self-expanding resilient permeable shell **40** having a proximal end **32**, a distal end **34**, a longitudinal axis **46** and further comprising a plurality of elongate resilient filaments **14** including large filaments **48** and small filaments **50** of at least two different transverse dimensions as shown in more detail in FIGS. 5, 7 and 18. The filaments **14** have a woven structure and are secured relative to each other at proximal ends **60** and distal ends **62** thereof. The permeable shell **40** of the device has a radially constrained elongated state configured for delivery within a microcatheter **61**, as shown in FIG. 11, with the thin woven filaments **14** extending longitudinally from the proximal end **42** to the distal end **44** radially adjacent each other along a length of the filaments.

As shown in FIGS. 3-6, the permeable shell **40** also has an expanded relaxed state with a globular and longitudinally shortened configuration relative to the radially constrained state. In the expanded state, the woven filaments **14** form the self-expanding resilient permeable shell **40** in a smooth path radially expanded from a longitudinal axis **46** of the device between the proximal end **32** and distal end **34**. The woven structure of the filaments **14** includes a plurality of openings **64** in the permeable shell **40** formed between the woven filaments. For some embodiments, the largest of said openings **64** may be configured to allow blood flow through the openings only at a velocity below a thrombotic threshold velocity. Thrombotic threshold velocity has been defined, at least by some, as the time-average velocity at which more than 50% of a vascular graft surface is covered by thrombus when deployed within a patient's vasculature. In the context of aneurysm occlusion, a slightly different threshold may be appropriate. Accordingly, the thrombotic threshold velocity as used herein shall include the velocity at which clotting occurs within or on a device, such as device **10**, deployed within a patient's vasculature such that blood flow into a vascular defect treated by the device is substantially blocked in less than about 1 hour or otherwise during the treatment procedure. The blockage of blood flow into the vascular defect may be indicated in some cases by minimal contrast agent entering the vascular defect after a sufficient amount of contrast agent has been injected into the patient's vasculature upstream of the implant site and visualized as it dissipates from that site. Such sustained blockage of flow within less than about 1 hour or during the duration of the implantation procedure may also be referred to as acute occlusion of the vascular defect.

As such, once the device **10** is deployed, any blood flowing through the permeable shell may be slowed to a velocity below the thrombotic threshold velocity and thrombus will begin to form on and around the openings in the permeable shell **40**. Ultimately, this process may be configured to produce acute occlusion of the vascular defect within which the device **10** is deployed. For some embodiments, at least the distal end of the permeable shell **40** may have a reverse bend in an everted configuration such that the secured distal ends **62** of the filaments **14** are withdrawn axially within the nominal permeable shell structure or contour in the expanded state. For some embodiments, the proximal end of the permeable shell further includes a reverse bend in an everted configuration such that the secured proximal ends **60** of the filaments **14** are withdrawn axially within the nominal permeable shell structure **40** in the expanded state. As used herein, the term everted may include a structure that is everted, partially everted and/or recessed with a reverse bend as shown in the device embodiment of FIGS. 3-6. For such embodiments, the ends **60** and **62** of the filaments **14** of the permeable shell or hub structure disposed around the ends may be withdrawn within or below the globular shaped periphery of the permeable shell of the device.

The elongate resilient filaments **14** of the permeable shell **40** may be secured relative to each other at proximal ends **60** and distal ends **62** thereof by one or more methods including welding, soldering, adhesive bonding, epoxy bonding or the like. In addition to the ends of the filaments being secured together, a distal hub **66** may also be secured to the distal ends **62** of the thin filaments **14** of the permeable shell **40** and a proximal hub **68** secured to the proximal ends **60** of the thin filaments **14** of the permeable shell **40**. The proximal hub **68** may include a cylindrical member that extends proximally beyond the proximal ends **60** of the thin filaments so as to form a cavity **70** within a proximal portion of the proximal

11

hub 68. The proximal cavity 70 may be used for holding adhesives such as epoxy, solder or any other suitable bonding agent for securing an elongate detachment tether 72 that may in turn be detachably secured to a delivery apparatus such as is shown in FIGS. 11-15.

For some embodiments, the elongate resilient filaments 14 of the permeable shell 40 may have a transverse cross section that is substantially round in shape and be made from a superelastic material that may also be a shape memory metal. The shape memory metal of the filaments of the permeable shell 40 may be heat set in the globular configuration of the relaxed expanded state as shown in FIGS. 3-6. Suitable superelastic shape memory metals may include alloys such as NiTi alloy and the like. The superelastic properties of such alloys may be useful in providing the resilient properties to the elongate filaments 14 so that they can be heat set in the globular form shown, fully constrained for delivery within an inner lumen of a microcatheter and then released to self expand back to substantially the original heat set shape of the globular configuration upon deployment within a patient's body.

The device 10 may have an everted filamentary structure with a permeable shell 40 having a proximal end 32 and a distal end 34 in an expanded relaxed state. The permeable shell 40 has a substantially enclosed configuration for the embodiment shown. Some or all of the permeable shell 40 of the device 10 may be configured to substantially block or impede fluid flow or pressure into a vascular defect or otherwise isolate the vascular defect over some period of time after the device is deployed in an expanded state. The permeable shell 40 and device 10 generally also has a low profile, radially constrained state, as shown in FIG. 11, with an elongated tubular or cylindrical configuration that includes the proximal end 32, the distal end 34 and a longitudinal axis 46. While in the radially constrained state, the elongate flexible filaments 14 of the permeable shell 40 may be disposed substantially parallel and in close lateral proximity to each other between the proximal end and distal end forming a substantially tubular or compressed cylindrical configuration.

Proximal ends 60 of at least some of the filaments 14 of the permeable shell 40 may be secured to the proximal hub 68 and distal ends 62 of at least some of the filaments 14 of the permeable shell 40 are secured to the distal hub 66, with the proximal hub 68 and distal hub 66 being disposed substantially concentric to the longitudinal axis 46 as shown in FIG. 4. The ends of the filaments 14 may be secured to the respective hubs 66 and 68 by any of the methods discussed above with respect to securement of the filament ends to each other, including the use of adhesives, solder, welding and the like. In some cases, hubs may be made from a highly radiopaque material such as platinum, platinum alloy (e.g. 90% platinum/10% iridium), or gold. A middle portion 30 of the permeable shell 40 may have a first transverse dimension with a low profile suitable for delivery from a microcatheter as shown in FIG. 11. Radial constraint on the device 10 may be applied by an inside surface of the inner lumen of a microcatheter, such as the distal end portion of the microcatheter 61 shown, or it may be applied by any other suitable mechanism that may be released in a controllable manner upon ejection of the device 10 from the distal end of the catheter. In FIG. 11 a proximal end or hub 68 of the device 10 is secured to a distal end of an elongate delivery apparatus 110 of a delivery system 112 disposed at the proximal hub 68 of the device 10.

Some device embodiments 10 having a braided or woven filamentary structure may be formed using about 10 filaments to about 300 filaments 14, more specifically, about 10 filaments to about 100 filaments 14, and even more specifically,

12

about 60 filaments to about 80 filaments 14. Some embodiments of a permeable shell 40 may include about 70 filaments to about 300 filaments extending from the proximal end 32 to the distal end 34, more specifically, about 100 filaments to about 200 filaments extending from the proximal end 32 to the distal end 34. For some embodiments, the filaments 14 may have a transverse dimension or diameter of about 0.0008 inches to about 0.004 inches. The elongate resilient filaments 14 in some cases may have an outer transverse dimension or diameter of about 0.0005 inch to about 0.005 inch, more specifically, about 0.001 inch to about 0.003 inch, and in some cases about 0.0004 inches to about 0.002 inches. For some device embodiments 10 that include filaments 14 of different sizes, the large filaments 48 of the permeable shell 40 may have a transverse dimension or diameter that is about 0.001 inches to about 0.004 inches and the small filaments 50 may have a transverse dimension or diameter of about 0.0004 inches to about 0.0015 inches, more specifically, about 0.0004 inches to about 0.001 inches. In addition, a difference in transverse dimension or diameter between the small filaments 50 and the large filaments 48 may be less than about 0.004 inches, more specifically, less than about 0.0035 inches, and even more specifically, less than about 0.002 inches. For embodiments of permeable shells 40 that include filaments 14 of different sizes, the number of small filaments 50 of the permeable shell 40 relative to the number of large filaments 48 of the permeable shell 40 may be about 2 to 1 to about 15 to 1, more specifically, about 2 to 1 to about 12 to 1, and even more specifically, about 4 to 1 to about 8 to 1.

The expanded relaxed state of the permeable shell 40, as shown in FIG. 4, has an axially shortened configuration relative to the constrained state such that the proximal hub 68 is disposed closer to the distal hub 66 than in the constrained state. Both hubs 66 and 68 are disposed substantially concentric to the longitudinal axis 46 of the device and each filamentary element 14 forms a smooth arc between the proximal and distal hubs 66 and 68 with a reverse bend at each end. A longitudinal spacing between the proximal and distal hubs 66 and 68 of the permeable shell 40 in a deployed relaxed state may be about 25 percent to about 75 percent of the longitudinal spacing between the proximal and distal hubs 66 and 68 in the constrained cylindrical state, for some embodiments. The arc of the filaments 14 between the proximal and distal ends 32 and 34 may be configured such that a middle portion of each filament 14 has a second transverse dimension substantially greater than the first transverse dimension.

For some embodiments, the permeable shell 40 may have a first transverse dimension in a collapsed radially constrained state of about 0.2 mm to about 2 mm and a second transverse dimension in a relaxed expanded state of about 4 mm to about 30 mm. For some embodiments, the second transverse dimension of the permeable shell 40 in an expanded state may be about 2 times to about 150 times the first transverse dimension, more specifically, about 10 times to about 25 times the first or constrained transverse dimension. A longitudinal spacing between the proximal end 32 and distal end 34 of the permeable shell 40 in the relaxed expanded state may be about 25% percent to about 75% percent of the spacing between the proximal end 32 and distal end 34 in the constrained cylindrical state. For some embodiments, a major transverse dimension of the permeable shell 40 in a relaxed expanded state may be about 4 mm to about 30 mm, more specifically, about 9 mm to about 15 mm, and even more specifically, about 4 mm to about 8 mm.

An arced portion of the filaments 14 of the permeable shell 40 may have a sinusoidal-like shape with a first or outer radius 88 and a second or inner radius 90 near the ends of the

13

permeable shell 40 as shown in FIG. 6. This sinusoid-like or multiple curve shape may provide a concavity in the proximal end 32 that may reduce an obstruction of flow in a parent vessel adjacent a vascular defect. For some embodiments, the first radius 88 and second radius 90 of the permeable shell 40 may be between about 0.12 mm to about 3 mm. For some embodiments, the distance between the proximal end 32 and distal end 34 may be less than about 60% of the overall length of the permeable shell 40 for some embodiments. Such a configuration may allow for the distal end 34 to flex downward toward the proximal end 32 when the device 10 meets resistance at the distal end 34 and thus may provide longitudinal conformance. The filaments 14 may be shaped in some embodiments such that there are no portions that are without curvature over a distance of more than about 2 mm. Thus, for some embodiments, each filament 14 may have a substantially continuous curvature. This substantially continuous curvature may provide smooth deployment and may reduce the risk of vessel perforation. For some embodiments, one of the ends 32 or 34 may be retracted or everted to a greater extent than the other so as to be more longitudinally or axially conformal than the other end.

The first radius 88 and second radius 90 of the permeable shell 40 may be between about 0.12 mm to about 3 mm for some embodiments. For some embodiments, the distance between the proximal end 32 and distal end 34 may be more than about 60% of the overall length of the expanded permeable shell 40. Thus, the largest longitudinal distance between the inner surfaces may be about 60% to about 90% of the longitudinal length of the outer surfaces or the overall length of device 10. A gap between the hubs 66 and 68 at the proximal end 32 and distal end 34 may allow for the distal hub 66 to flex downward toward the proximal hub 68 when the device 10 meets resistance at the distal end and thus provides longitudinal conformance. The filaments 14 may be shaped such that there are no portions that are without curvature over a distance of more than about 2 mm. Thus, for some embodiments, each filament 14 may have a substantially continuous curvature. This substantially continuous curvature may provide smooth deployment and may reduce the risk of vessel perforation. The distal end 34 may be retracted or everted to a greater extent than the proximal end 32 such that the distal end portion of the permeable shell 40 may be more radially conformal than the proximal end portion. Conformability of a distal end portion may provide better device conformance to irregular shaped aneurysms or other vascular defects. A convex surface of the device may flex inward forming a concave surface to conform to curvature of a vascular site.

FIG. 10 shows an enlarged view of the filaments 14 disposed within a proximal hub 68 of the device 10 with the filaments 14 of two different sizes constrained and tightly packed by an outer ring of the proximal hub 68. The tether member 72 may optionally be disposed within a middle portion of the filaments 14 or within the cavity 70 of the proximal hub 68 proximal of the proximal ends 60 of the filaments 14 as shown in FIG. 6. The distal end of the tether 72 may be secured with a knot 92 formed in the distal end thereof which is mechanically captured in the cavity 70 of the proximal hub 68 formed by a proximal shoulder portion 94 of the proximal hub 68. The knotted distal end 92 of the tether 72 may also be secured by bonding or potting of the distal end of the tether 72 within the cavity 70 and optionally amongst the proximal ends 60 of the filaments 14 with mechanical compression, adhesive bonding, welding, soldering, brazing or the like. The tether embodiment 72 shown in FIG. 6 has a knotted distal end 92 potted in the cavity of the proximal hub 68 with an adhesive. Such a tether 72 may be a dissolvable, severable or

14

releasable tether that may be part of a delivery apparatus 110 used to deploy the device 10 as shown in FIG. 11 and FIGS. 23-26. FIG. 10 also shows the large filaments 48 and small filaments 50 disposed within and constrained by the proximal hub 68 which may be configured to secure the large and small filaments 48 and 50 in place relative to each other within the outer ring of the proximal hub 68.

FIGS. 7 and 8 illustrate some configuration embodiments of braided filaments 14 of a permeable shell 40 of the device 10 for treatment of a patient's vasculature. The braid structure in each embodiment is shown with a circular shape 100 disposed within a pore 64 of a woven or braided structure with the circular shape 100 making contact with each adjacent filament segment. The pore opening size may be determined at least in part by the size of the filament elements 14 of the braid, the angle overlapping filaments make relative to each other and the picks per inch of the braid structure. For some embodiments, the cells or openings 64 may have an elongated substantially diamond shape as shown in FIG. 7, and the pores or openings 64 of the permeable shell 40 may have a substantially more square shape toward a middle portion 30 of the device 10, as shown in FIG. 8. The diamond shaped pores or openings 64 may have a length substantially greater than the width particularly near the hubs 66 and 68. In some embodiments, the ratio of diamond shaped pore or opening length to width may exceed a ratio of 3 to 1 for some cells. The diamond-shaped openings 64 may have lengths greater than the width thus having an aspect ratio, defined as Length/Width of greater than 1. The openings 64 near the hubs 66 and 68 may have substantially larger aspect ratios than those farther from the hubs as shown in FIG. 7. The aspect ratio of openings 64 adjacent the hubs may be greater than about 4 to 1. The aspect ratio of openings 64 near the largest diameter may be between about 0.75 to 1 and about 2 to 1 for some embodiments. For some embodiments, the aspect ratio of the openings 64 in the permeable shell 40 may be about 0.5 to 1 to about 2 to 1.

The pore size defined by the largest circular shapes 100 that may be disposed within openings 64 of the braided structure of the permeable shell 40 without displacing or distorting the filaments 14 surrounding the opening 64 may range in size from about 0.005 inches to about 0.01 inches, more specifically, about 0.006 inches to about 0.009 inches, even more specifically, about 0.007 inches to about 0.008 inches for some embodiments. In addition, at least some of the openings 64 formed between adjacent filaments 14 of the permeable shell 40 of the device 10 may be configured to allow blood flow through the openings 64 only at a velocity below a thrombotic threshold velocity. For some embodiments, the largest openings 64 in the permeable shell structure 40 may be configured to allow blood flow through the openings 64 only at a velocity below a thrombotic threshold velocity. As discussed above, the pore size may be less than about 0.016 inches, more specifically, less than about 0.012 inches for some embodiments. For some embodiments, the openings 64 formed between adjacent filaments 14 may be about 0.005 inches to about 0.04 inches.

Referring to FIGS. 12-15, a delivery apparatus embodiment 110 of the delivery system 112 of FIG. 11 is shown in more detail. The apparatus 110 includes an elongate core wire 114 that extends from a proximal end 116 of the apparatus 110 to a distal section 118 of the apparatus 110 as shown in FIG. 12. The core wire 114 is configured to provide sufficient column strength to push a constrained device 10 for treatment of a patient's vasculature through an inner lumen 120 of the microcatheter 61 of the delivery system 112 as shown in FIG. 11. The core wire 114 also has sufficient tensile strength to withdraw or proximally retract the device 10 from a position

15

outside the microcatheter **61** and axially within the inner lumen **120** of the microcatheter **61**. The tether **72** that extends proximally from the proximal hub **68** is secured to the distal end of the core wire **114** with a length of shrinkable tubing **122** that is disposed over a portion of the tether **72** and a distal section of the core wire **114** and shrunk over both as shown in FIG. **13**, although any other suitable means of securement may be used.

A heater coil **124** electrically coupled to a first conductor **126** and a second conductor **128** is disposed over a distal most portion of the tether **72**. The heater coil **124** may also be covered with a length of polymer tubing **130** disposed over the heater coil **124** distal of the heat shrink tubing **122** that serves to act as a heat shield and minimizes the leakage of heat from the heater coil **124** into the environment, such as the patient's blood stream, around the delivery apparatus **110**. Once the heat shrink tubing **122** and insulating polymer tubing **130** have been secured to the distal section **118** of the apparatus **110**, the proximal portion of the tether **72** disposed proximal of the heat shrink tubing **122** may be trimmed as shown in FIG. **13**. An over coil **132** that extends from a distal end **134** of the delivery apparatus **110** to a proximal section **136** of the apparatus **110** may then be disposed over the heater coil **124**, core wire **114**, tether **72**, first conductor **126** and second conductor **128** to hold these elements together, produce a low friction outer surface and maintain a desired flexibility of the delivery apparatus **110**. The proximal section **136** of the apparatus **110** includes the proximal terminus of the over coil **132** which is disposed distal of a first contact **138** and second contact **140** which are circumferentially disposed about the proximal section **136** of the core wire **114**, insulated therefrom, and electrically coupled to the first conductor **126** and second conductor **128**, respectively as shown in FIG. **15**.

The heater coil **124** may be configured to receive electric current supplied through the first conductor **126** and second conductor **128** from an electrical energy source **142** coupled to the first contact **138** and second contact **140** at the proximal section **136** of the apparatus **110**. The electrical current passed through the heater coil **124** heats the heater coil to a temperature above the melting point of the tether material **72** so as to melt the tether **72** and sever it upon deployment of the device **10**.

Embodiments of the delivery apparatus **110** may generally have a length greater than the overall length of a microcatheter **61** to be used for the delivery system **112**. This relationship allows the delivery apparatus **110** to extend, along with the device **10** secured to the distal end thereof, from the distal port of the inner lumen **120** of the microcatheter **61** while having sufficient length extending from a proximal end **150** of the microcatheter **61**, shown in FIG. **17** discussed below, to enable manipulation thereof by a physician. For some embodiments, the length of the delivery apparatus **110** may be about 170 cm to about 200 cm. The core wire **114** may be made from any suitable high strength material such as stainless steel, NiTi alloy, or the like. Embodiments of the core wire **114** may have an outer diameter or transverse dimension of about 0.010 inch to about 0.015 inch. The over coil **132** may have an outer diameter or transverse dimension of about 0.018 inch to about 0.03 inch. Although the apparatus embodiment **110** shown in FIGS. **12-15** is activated by electrical energy passed through a conductor pair, a similar configuration that utilizes light energy passed through a fiber optic or any other suitable arrangement could be used to remotely heat a distal heating member or element such as the heater coil **124** to sever the distal portion of the tether **72**. In addition, other delivery apparatus embodiments are discussed

16

and incorporated herein that may also be used for any of the device embodiments **10** for treatment of a patient's vasculature discussed herein.

Other delivery and positioning system embodiments may provide for the ability to rotate a device for treatment of a patient's vasculature in-vivo without translating torque along the entire length of the delivery apparatus. Some embodiments for delivery and positioning of devices **10** are described in co-owned International PCT Patent Application No. PCT/US2008/065694 which is incorporated by reference herein in its entirety. The delivery and positioning apparatus may include a distal rotating member that allows rotational positioning of the device. The delivery and positioning apparatus may include a distal rotating member which rotates an implant in-vivo without the transmission of torque along the entire length of the apparatus. Optionally, delivery system may also rotate the implant without the transmission of torque in the intermediate portion between the proximal end and the distal rotatable end. The delivery and positioning apparatus may be releasably secured to any suitable portion of the device for treatment of a patient's vasculature.

Device embodiments discussed herein may be releasable from any suitable flexible, elongate delivery apparatus or actuator such as a guidewire or guidewire-like structure. The release of device embodiments from such a delivery apparatus may be activated by a thermal mechanism, as discussed above, electrolytic mechanism, hydraulic mechanism, shape memory material mechanism, or any other mechanism known in the art of endovascular implant deployment.

Embodiments for deployment and release of therapeutic devices, such as deployment of embolic devices or stents within the vasculature of a patient, may include connecting such a device via a releasable connection to a distal portion of a pusher or other delivery apparatus member. The therapeutic device **10** may be detachably mounted to the distal portion of the apparatus by a filamentary tether **72**, string, thread, wire, suture, fiber, or the like, which may be referred to above as the tether. The tether **72** may be in the form of a monofilament, rod, ribbon, hollow tube, or the like. Some embodiments of the tether may have a diameter or maximum thickness of between about 0.05 mm and 0.2 mm. The tether **72** may be configured to be able to withstand a maximum tensile load of between about 0.5 kg and 5 kg. For some embodiments, due to the mass of the device **10** being deployed which may be substantially greater than some embolic devices, some known detachment devices may lack sufficient tensile strength to be used for some embodiments discussed herein. As such, it may be desirable to use small very high strength fibers for some tether embodiments having a "load at break" greater than about 15 Newtons. For some embodiments, a tether made from a material known as Dyneema Purity available from Royal DSM, Heerlen, Netherlands may be used.

The tether **72** may be severed by the input of energy such as electric current to a heating element causing release of the therapeutic device. For some embodiments, the heating element may be a coil of wire with high electrical resistivity such as a platinum-tungsten alloy. The tether member may pass through or be positioned adjacent the heater element. The heater may be contained substantially within the distal portion of the delivery apparatus to provide thermal insulation to reduce the potential for thermal damage to the surrounding tissues during detachment. In another embodiment, current may pass through the tether which also acts as a heating element.

Many materials may be used to make tether embodiments **72** including polymers, metals and composites thereof. One class of materials that may be useful for tethers includes

17

polymers such as polyolefin, polyolefin elastomer such as polyethylene, polyester (PET), polyamide (Nylon), polyurethane, polypropylene, block copolymer such as PEBAX or Hytrel, and ethylene vinyl alcohol (EVA); or rubbery materials such as silicone, latex, and Kraton. In some cases, the polymer may also be cross-linked with radiation to manipulate its tensile strength and melt temperature. Another class of materials that may be used for tether embodiment may include metals such as nickel titanium alloy (Nitinol), gold, platinum, tantalum and steel. Other materials that may be useful for tether construction includes wholly aromatic polyester polymers which are liquid crystal polymers (LCP) that may provide high performance properties and are highly inert. A commercially available LCP polymer is Vectran, which is produced by Kuraray Co. (Tokyo, Japan). The selection of the material may depend on the melting or softening temperature, the power used for detachment, and the body treatment site. The tether may be joined to the implant and/or the pusher by crimping, welding, knot tying, soldering, adhesive bonding, or other means known in the art.

It should be noted also that many variations of filament and proximal hub construction such as is detailed above with regard to FIG. 10 may be used for useful embodiments of a device for treatment of a patient's vasculature 10. FIG. 16 shows an enlarged view in transverse cross section of a proximal hub configuration. For the embodiment shown, the filaments 14 are disposed within a proximal hub 68 or end portion of the device 10 with the filaments 14 constrained and tightly packed by an outer ring of the proximal hub 68. A tether member 72 may be disposed within a middle portion of the filaments 14 or within a cavity of the proximal hub 68 proximal of the proximal ends 60 of the filaments 14. Such a tether 72 may be a dissolvable, severable or releasable tether that may be part of a release apparatus as discussed above used to deploy the device.

FIG. 16 illustrates in transverse cross section an embodiment of a proximal hub 68 showing the configuration of filaments which may be tightly packed and radially constrained by an inside surface of the proximal hub 68. In some embodiments, the braided or woven structure of the permeable shell 40 formed from such filaments 14 may be constructed using a large number of small filaments. The number of filaments 14 may be greater than 125 and may also be between about 80 filaments and about 180 filaments. As discussed above, the total number of filaments 14 for some embodiments may be about 70 filaments to about 300 filaments, more specifically, about 100 filaments to about 200 filaments. In some embodiments, the braided structure of the permeable shell 40 may be constructed with two or more sizes of filaments 14. For example, the structure may have several larger filaments that provide structural support and several smaller filaments that provide the desired pore size and density and thus flow resistance to achieve a thrombotic threshold velocity in some cases. For some embodiments, small filaments 50 of the permeable shell 40 may have a transverse dimension or diameter of about 0.0006 inches to about 0.002 inches for some embodiments and about 0.0004 inches to about 0.001 inches in other embodiments. The large filaments 48 may have a transverse dimension or diameter of about 0.0015 inches to about 0.004 inches in some embodiments and about 0.001 inches to about 0.004 inches in other embodiments. The filaments 14 may be braided in a plain weave that is one under, one over structure (shown in FIGS. 7 and 8) or a supplementary weave; more than one warp interlace with one or more than one weft. The pick count may be varied between about 25 and 200 picks per inch (PPI).

18

For some embodiments, the permeable shell 40 or portions thereof may be porous and may be highly permeable to liquids. In contrast to most vascular prosthesis fabrics or grafts which typically have a water permeability below 2,000 ml/min/cm<sup>2</sup> when measured at a pressure of 120 mmHg, the permeable shell 40 of some embodiments discussed herein may have a water permeability greater than about 2,000 ml/min/cm<sup>2</sup>, in some cases greater than about 2,500 ml/min/cm<sup>2</sup>. For some embodiments, water permeability of the permeable shell 40 or portions thereof may be between about 2,000 and 10,000 ml/min/cm<sup>2</sup>, more specifically, about 2,000 ml/min/cm<sup>2</sup> to about 15,000 ml/min/cm<sup>2</sup>, when measured at a pressure of 120 mmHg.

Device embodiments and components thereof may include metals, polymers, biologic materials and composites thereof. Suitable metals include zirconium-based alloys, cobalt-chrome alloys, nickel-titanium alloys, platinum, tantalum, stainless steel, titanium, gold, and tungsten. Potentially suitable polymers include but are not limited to acrylics, silk, silicones, polyvinyl alcohol, polypropylene, polyvinyl alcohol, polyesters (e.g. polyethylene terephthalate or PET), PolyEtherEther Ketone (PEEK), polytetrafluoroethylene (PTFE), polycarbonate urethane (PCU) and polyurethane (PU). Device embodiments may include a material that degrades or is absorbed or eroded by the body. A bioresorbable (e.g., breaks down and is absorbed by a cell, tissue, or other mechanism within the body) or bioabsorbable (similar to bioresorbable) material may be used. Alternatively, a bioerodable (e.g., erodes or degrades over time by contact with surrounding tissue fluids, through cellular activity or other physiological degradation mechanisms), biodegradable (e.g., degrades over time by enzymatic or hydrolytic action, or other mechanism in the body), or dissolvable material may be employed. Each of these terms is interpreted to be interchangeable. bioabsorbable polymer. Potentially suitable bioabsorbable materials include polylactic acid (PLA), poly(alpha-hydroxy acid) such as poly-L-lactide (PLLA), poly-D-lactide (PDLA), polyglycolide (PGA), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), or related copolymer materials. An absorbable composite fiber may be made by combining a reinforcement fiber made from a copolymer of about 18% glycolic acid and about 82% lactic acid with a matrix material consisting of a blend of the above copolymer with about 20% polycaprolactone (PCL).

In any of the suitable device embodiments 10 discussed herein, the permeable shell structure 40 may include one or more fixation elements or surfaces to facilitate fixation of the device within a blood vessel or other vascular site. The fixation elements may comprise hooks, barbs, protrusions, pores, microfeatures, texturing, bioadhesives or combinations thereof. Embodiments of the support structure may be fabricated from a tube of metal where portions are removed. The removal of material may be done by laser, electrical discharge machining (EDM), photochemical etching and traditional machining techniques. In any of the described embodiments, the support structure may be constructed with a plurality of wires, cut or etched from a sheet of a material, cut or etched from a tube or a combination thereof as in the art of vascular stent fabrication.

Permeable shell embodiments 40 may be formed at least in part of wire, ribbon, or other filamentary elements 14. These filamentary elements 14 may have circular, elliptical, ovoid, square, rectangular, or triangular cross-sections. Permeable shell embodiments 40 may also be formed using conventional

machining, laser cutting, electrical discharge machining (EDM) or photochemical machining (PCM). If made of a metal, it may be formed from either metallic tubes or sheet material.

Device embodiments **10** discussed herein may be delivered and deployed from a delivery and positioning system **112** that includes a microcatheter **61**, such as the type of microcatheter **61** that is known in the art of neurovascular navigation and therapy. Device embodiments for treatment of a patient's vasculature **10** may be elastically collapsed and restrained by a tube or other radial restraint, such as an inner lumen **120** of a microcatheter **61**, for delivery and deployment. The microcatheter **61** may generally be inserted through a small incision **152** accessing a peripheral blood vessel such as the femoral artery or brachial artery. The microcatheter **61** may be delivered or otherwise navigated to a desired treatment site **154** from a position outside the patient's body **156** over a guidewire **159** under fluoroscopy or by other suitable guiding methods. The guidewire **159** may be removed during such a procedure to allow insertion of the device **10** secured to a delivery apparatus **110** of the delivery system **112** through the inner lumen **120** of a microcatheter **61** in some cases. FIG. **17** illustrates a schematic view of a patient **158** undergoing treatment of a vascular defect **160** as shown in FIG. **18**. An access sheath **162** is shown disposed within either a radial artery **164** or femoral artery **166** of the patient **158** with a delivery system **112** that includes a microcatheter **61** and delivery apparatus **110** disposed within the access sheath **162**. The delivery system **112** is shown extending distally into the vasculature of the patient's brain adjacent a vascular defect **160** in the patient's brain.

Access to a variety of blood vessels of a patient may be established, including arteries such as the femoral artery **166**, radial artery **164**, and the like in order to achieve percutaneous access to a vascular defect **160**. In general, the patient **158** may be prepared for surgery and the access artery is exposed via a small surgical incision **152** and access to the lumen is gained using the Seldinger technique where an introducing needle is used to place a wire over which a dilator or series of dilators dilates a vessel allowing an introducer sheath **162** to be inserted into the vessel. This would allow the device to be used percutaneously. With an introducer sheath **162** in place, a guiding catheter **168** is then used to provide a safe passageway from the entry site to a region near the target site **154** to be treated. For example, in treating a site in the human brain, a guiding catheter **168** would be chosen which would extend from the entry site **152** at the femoral artery up through the large arteries extending around the heart through the aortic arch, and downstream through one of the arteries extending from the upper side of the aorta such as the carotid artery **170**. Typically, a guidewire **159** and neurovascular microcatheter **61** are then placed through the guiding catheter **168** and advanced through the patient's vasculature, until a distal end **151** of the microcatheter **61** is disposed adjacent or within the target vascular defect **160**, such as an aneurysm. Exemplary guidewires **159** for neurovascular use include the Synchro2® made by Boston Scientific and the Glidewire Gold Neuro® made by MicroVention Terumo. Typical guidewire sizes may include 0.014 inches and 0.018 inches. Once the distal end **151** of the catheter **61** is positioned at the site, often by locating its distal end through the use of radiopaque marker material and fluoroscopy, the catheter is cleared. For example, if a guidewire **159** has been used to position the microcatheter **61**, it is withdrawn from the catheter **61** and then the implant delivery apparatus **110** is advanced through the microcatheter **61**.

Delivery and deployment of device embodiments **10** discussed herein may be carried out by first compressing the device **10** to a radially constrained and longitudinally flexible state as shown in FIG. **11**. The device **10** may then be delivered to a desired treatment site **154** while disposed within the microcatheter **61**, and then ejected or otherwise deployed from a distal end **151** of the microcatheter **61**. In other method embodiments, the microcatheter **61** may first be navigated to a desired treatment site **154** over a guidewire **159** or by other suitable navigation techniques. The distal end of the microcatheter **61** may be positioned such that a distal port of the microcatheter **61** is directed towards or disposed within a vascular defect **160** to be treated and the guidewire **159** withdrawn. The device **10** secured to a suitable delivery apparatus **110** may then be radially constrained, inserted into a proximal portion of the inner lumen **120** of the microcatheter **61** and distally advanced to the vascular defect **160** through the inner lumen **120**.

Once disposed within the vascular defect **160**, the device **10** may then allowed to assume an expanded relaxed or partially relaxed state with the permeable shell **40** of the device spanning or partially spanning a portion of the vascular defect **160** or the entire vascular defect **160**. The device **10** may also be activated by the application of an energy source to assume an expanded deployed configuration once ejected from the distal section of the microcatheter **61** for some embodiments. Once the device **10** is deployed at a desired treatment site **154**, the microcatheter **61** may then be withdrawn.

Some embodiments of devices for the treatment of a patient's vasculature **10** discussed herein may be directed to the treatment of specific types of defects of a patient's vasculature. For example, referring to FIG. **18**, an aneurysm **160** commonly referred to as a terminal aneurysm is shown in section. Terminal aneurysms occur typically at bifurcations in a patient's vasculature where blood flow, indicated by the arrows **172**, from a supply vessel splits into two or more branch vessels directed away from each other. The main flow of blood from the supply vessel **174**, such as a basilar artery, sometimes impinges on the vessel where the vessel diverges and where the aneurysm sack forms. Terminal aneurysms may have a well defined neck structure where the profile of the aneurysm **160** narrows adjacent the nominal vessel profile, but other terminal aneurysm embodiments may have a less defined neck structure or no neck structure. FIG. **19** illustrates a typical berry type aneurysm **160** in section where a portion of a wall of a nominal vessel section weakens and expands into a sack like structure ballooning away from the nominal vessel surface and profile. Some berry type aneurysms may have a well defined neck structure as shown in FIG. **19**, but others may have a less defined neck structure or none at all. FIG. **19** also shows some optional procedures wherein a stent **173** or other type of support has been deployed in the parent vessel **174** adjacent the aneurysm. Also, shown is embolic material **176** being deposited into the aneurysm **160** through a microcatheter **61**. Either or both of the stent **173** and embolic material **176** may be so deployed either before or after the deployment of a device for treatment of a patient's vasculature **10**.

Prior to delivery and deployment of a device for treatment of a patient's vasculature **10**, it may be desirable for the treating physician to choose an appropriately sized device **10** to optimize the treatment results. Some embodiments of treatment may include estimating a volume of a vascular site or defect **160** to be treated and selecting a device **10** with a volume that is substantially the same volume or slightly oversized relative to the volume of the vascular site or defect **160**. The volume of the vascular defect **160** to be occluded may be

21

determined using three-dimensional angiography or other similar imaging techniques along with software which calculates the volume of a selected region. The amount of oversizing may be between about 2% and 15% of the measured volume. In some embodiments, such as a very irregular shaped aneurysm, it may be desirable to under-size the volume of the device 10. Small lobes or “daughter aneurysms” may be excluded from the volume, defining a truncated volume which may be only partially filled by the device without affecting the outcome. A device 10 deployed within such an irregularly shaped aneurysm 160 is shown in FIG. 28 discussed below. Such a method embodiment may also include implanting or deploying the device 10 so that the vascular defect 160 is substantially filled volumetrically by a combination of device and blood contained therein. The device 10 may be configured to be sufficiently conformal to adapt to irregular shaped vascular defects 160 so that at least about 75%, in some cases about 80%, of the vascular defect volume is occluded by a combination of device 10 and blood contained therein.

In particular, for some treatment embodiments, it may be desirable to choose a device 10 that is properly oversized in a transverse dimension so as to achieve a desired conformance, radial force and fit after deployment of the device 10. FIGS. 20-22 illustrate a schematic representation of how a device 10 may be chosen for a proper fit after deployment that is initially oversized in a transverse dimension by at least about 10% of the largest transverse dimension of the vascular defect 160 and sometimes up to about 100% of the largest transverse dimension. For some embodiments, the device 10 may be oversized a small amount (e.g. less than about 1.5 mm) in relation to measured dimensions for the width, height or neck diameter of the vascular defect 160.

In FIG. 20, a vascular defect 160 in the form of a cerebral aneurysm is shown with horizontal arrows 180 and vertical arrows 182 indicating the approximate largest interior dimensions of the defect 160. Arrow 180 extending horizontally indicates the largest transverse dimension of the defect 160. In FIG. 21, a dashed outline 184 of a device for treatment of the vascular defect 10 is shown superimposed over the vascular defect 160 of FIG. 20 illustrating how a device 10 that has been chosen to be approximately 20% oversized in a transverse dimension would look in its unconstrained, relaxed state. FIG. 22 illustrates how the device 10 which is indicated by the dashed line 184 of FIG. 21 might conform to the interior surface of the vascular defect 160 after deployment whereby the nominal transverse dimension of the device 10 in a relaxed unconstrained state has now been slightly constrained by the inward radial force 185 exerted by the vascular defect 160 on the device 10. In response, as the filaments 14 of the device 10 and thus the permeable shell 40 made therefrom have a constant length, the device 10 has assumed a slightly elongated shape in the axial or longitudinal axis of the device 10 so as to elongate and better fill the interior volume of the defect 160 as indicated by the downward arrow 186 in FIG. 22.

Once a properly sized device 10 has been selected, the delivery and deployment process may then proceed. It should also be noted also that the properties of the device embodiments 10 and delivery system embodiments 112 discussed herein generally allow for retraction of a device 10 after initial deployment into a defect 160, but before detachment of the device 10. Therefore, it may also be possible and desirable to withdraw or retrieve an initially deployed device 10 after the fit within the defect 160 has been evaluated in favor of a differently sized device 10. An example of a terminal aneurysm 160 is shown in FIG. 23 in section. The tip 151 of a

22

catheter, such as a microcatheter 61 may be advanced into or adjacent the vascular site or defect 160 (e.g. aneurysm) as shown in FIG. 24. For some embodiments, an embolic coil or other vaso-occlusive device or material 176 (as shown for example in FIG. 19) may optionally be placed within the aneurysm 160 to provide a framework for receiving the device 10. In addition, a stent 173 may be placed within a parent vessel 174 of some aneurysms substantially crossing the aneurysm neck prior to or during delivery of devices for treatment of a patient's vasculature discussed herein (also as shown for example in FIG. 19). An example of a suitable microcatheter 61 having an inner lumen diameter of about 0.020 inches to about 0.022 inches is the Rapid Transit® manufactured by Cordis Corporation. Examples of some suitable microcatheters 61 may include microcatheters having an inner lumen diameter of about 0.026 inch to about 0.028 inch, such as the Rebar® by Ev3 Company, the Renegade Hi-Flow® by Boston Scientific Corporation, and the Mass Transit® by Cordis Corporation. Suitable microcatheters having an inner lumen diameter of about 0.031 inch to about 0.033 inch may include the Marksmen® by Chestnut Medical Technologies, Inc. and the Vasco 28® by Balt Extrusion. A suitable microcatheter 61 having an inner lumen diameter of about 0.039 inch to about 0.041 inch includes the Vasco 35 by Balt Extrusion. These microcatheters 61 are listed as exemplary embodiments only, other suitable microcatheters may also be used with any of the embodiments discussed herein.

Detachment of the device 10 from the delivery apparatus 110 may be controlled by a control switch 188 disposed at a proximal end of the delivery system 112, which may also be coupled to an energy source 142, which severs the tether 72 that secures the proximal hub 68 of the device 10 to the delivery apparatus 110. While disposed within the microcatheter 61 or other suitable delivery system 112, as shown in FIG. 11, the filaments 14 of the permeable shell 40 may take on an elongated, non-everted configuration substantially parallel to each other and a longitudinal axis of the catheter 61. Once the device 10 is pushed out of the distal port of the microcatheter 61, or the radial constraint is otherwise removed, the distal ends 62 of the filaments 14 may then axially contract towards each other so as to assume the globular everted configuration within the vascular defect 160 as shown in FIG. 25.

The device 10 may be inserted through the microcatheter 61 such that the catheter lumen 120 restrains radial expansion of the device 10 during delivery. Once the distal tip or deployment port of the delivery system 112 is positioned in a desirable location adjacent or within a vascular defect 160, the device 10 may be deployed out the distal end of the catheter 61 thus allowing the device to begin to radially expand as shown in FIG. 25. As the device 10 emerges from the distal end of the delivery system 112, the device 10 expands to an expanded state within the vascular defect 160, but may be at least partially constrained by an interior surface of the vascular defect 160.

Upon full deployment, radial expansion of the device 10 may serve to secure the device 10 within the vascular defect 160 and also deploy the permeable shell 40 across at least a portion of an opening 190 (e.g. aneurysm neck) so as to at least partially isolate the vascular defect 160 from flow, pressure or both of the patient's vasculature adjacent the vascular defect 160 as shown in FIG. 26. The conformability of the device 10, particularly in the neck region 190 may provide for improved sealing. For some embodiments, once deployed, the permeable shell 40 may substantially slow flow of fluids and impede flow into the vascular site and thus reduce pressure within the vascular defect 160. For some embodiments, the device 10 may be implanted substantially within the vas-



23

cular defect **160**, however, in some embodiments, a portion of the device **10** may extend into the defect opening or neck **190** or into branch vessels.

One exemplary case study that has been conducted includes a procedure performed on a female canine where an aneurysm was surgically created in the subject canine. The target aneurysm prior to treatment had a maximum transverse dimension of about 8 mm, a length of about 10 mm and a neck measurement of about 5.6 mm. The device **10** deployed included a permeable shell **40** formed of 144 resilient filaments having a transverse diameter of about 0.0015 inches braided into a globular structure having a transverse dimension of about 10 mm and a longitudinal length of about 7 mm in a relaxed expanded state. The maximum size **100** of the pores **64** of the expanded deployed permeable shell **40** was about 0.013 inches. The device was delivered to the target aneurysm using a 5 Fr. Guider Softip XF guide catheter made by Boston Scientific. The maximum size **100** of the pores **64** of the portion of the expanded deployed permeable shell **40** that spanned the neck of the aneurysm again was about 0.013 inches. Five minutes after detachment from the delivery system, the device **10** had produced acute occlusion of the aneurysm.

Another exemplary case study conducted involved treatment of a surgically created aneurysm in a New Zealand White Rabbit. The target aneurysm prior to treatment had a maximum transverse dimension of about 3.6 mm, length of about 5.8 mm and a neck measurement of about 3.4 mm. The device **10** deployed included a permeable shell formed of 144 resilient filaments having a transverse diameter of about 0.001 inches braided into a globular structure having a transverse dimension of about 4 mm and a length of about 5 mm in a relaxed expanded state. The pore size **100** of the portion of the braided mesh of the expanded deployed permeable shell **40** that was configured to span the neck of the vascular defect was about 0.005 inches. The device was delivered to the surgically created aneurysm with a 5 Fr. Envoy STR guide catheter manufactured by Cordis Neurovascular. A Renegade Hi-Flo microcatheter manufactured by Boston Scientific having an inner lumen diameter of about 0.027 inches was then inserted through the guide catheter and served as a conduit for delivery of the device **10** secured to a distal end of a delivery apparatus. Once the device **10** was deployed within the vascular defect **160**, the vascular defect **160** achieved at least partial occlusion at 5 minutes from implantation. However, due to the sensitivity of the subject animal to angiographic injection and measurement, no further data was taken during the procedure. Complete occlusion was observed for the device when examined at 3 weeks from the procedure.

For some embodiments, as discussed above, the device **10** may be manipulated by the user to position the device **10** within the vascular site or defect **160** during or after deployment but prior to detachment. For some embodiments, the device **10** may be rotated in order to achieve a desired position of the device **10** and, more specifically, a desired position of the permeable shell **40**, prior to or during deployment of the device **10**. For some embodiments, the device **10** may be rotated about a longitudinal axis of the delivery system **112** with or without the transmission or manifestation of torque being exhibited along a middle portion of a delivery catheter being used for the delivery. It may be desirable in some circumstances to determine whether acute occlusion of the vascular defect **160** has occurred prior to detachment of the device **10** from the delivery apparatus **110** of the delivery system **112**. These delivery and deployment methods may be used for deployment within berry aneurysms, terminal aneurysms, or any other suitable vascular defect embodiments

24

**160**. Some method embodiments include deploying the device **10** at a confluence of three vessels of the patient's vasculature that form a bifurcation such that the permeable shell **40** of the device **10** substantially covers the neck of a terminal aneurysm. Once the physician is satisfied with the deployment, size and position of the device **10**, the device **10** may then be detached by actuation of the control switch **188** by the methods described above and shown in FIG. **26**. Thereafter, the device **10** is in an implanted state within the vascular defect **160** to effect treatment thereof.

FIG. **27** illustrates another configuration of a deployed and implanted device in a patient's vascular defect **160**. While the implantation configuration shown in FIG. **26** indicates a configuration whereby the longitudinal axis **46** of the device **10** is substantially aligned with a longitudinal axis of the defect **160**, other suitable and clinically effective implantation embodiments may be used. For example, FIG. **27** shows an implantation embodiment whereby the longitudinal axis **46** of the implanted device **10** is canted at an angle of about 10 degrees to about 90 degrees relative to a longitudinal axis of the target vascular defect **160**. Such an alternative implantation configuration may also be useful in achieving a desired clinical outcome with acute occlusion of the vascular defect **160** in some cases and restoration of normal blood flow adjacent the treated vascular defect. FIG. **28** illustrates a device **10** implanted in an irregularly shaped vascular defect **160**. The aneurysm **160** shown has at least two distinct lobes **192** extending from the main aneurysm cavity. The two lobes **192** shown are unfilled by the deployed vascular device **10**, yet the lobes **192** are still isolated from the parent vessel of the patient's body due to the occlusion of the aneurysm neck portion **190**.

Markers, such as radiopaque markers, on the device **10** or delivery system **112** may be used in conjunction with external imaging equipment (e.g. x-ray) to facilitate positioning of the device or delivery system during deployment. Once the device is properly positioned, the device **10** may be detached by the user. For some embodiments, the detachment of the device **10** from the delivery apparatus **110** of the delivery system **112** may be affected by the delivery of energy (e.g. heat, radiofrequency, ultrasound, vibrational, or laser) to a junction or release mechanism between the device **10** and the delivery apparatus **110**. Once the device **10** has been detached, the delivery system **112** may be withdrawn from the patient's vasculature or patient's body **158**. For some embodiments, a stent **173** may be placed within the parent vessel substantially crossing the aneurysm neck **190** after delivery of the device **10** as shown in FIG. **19** for illustration.

For some embodiments, a biologically active agent or a passive therapeutic agent may be released from a responsive material component of the device **10**. The agent release may be affected by one or more of the body's environmental parameters or energy may be delivered (from an internal or external source) to the device **10**. Hemostasis may occur within the vascular defect **160** as a result of the isolation of the vascular defect **160**, ultimately leading to clotting and substantial occlusion of the vascular defect **160** by a combination of thrombotic material and the device **10**. For some embodiments, thrombosis within the vascular defect **160** may be facilitated by agents released from the device **10** and/or drugs or other therapeutic agents delivered to the patient.

For some embodiments, once the device **10** has been deployed, the attachment of platelets to the permeable shell **40** may be inhibited and the formation of clot within an interior space of the vascular defect **160**, device, or both promoted or otherwise facilitated with a suitable choice of thrombogenic coatings, anti-thrombogenic coatings or any



other suitable coatings (not shown) which may be disposed on any portion of the device **10** for some embodiments, including an outer surface of the filaments **14** or the hubs **66** and **68**. Such a coating or coatings may be applied to any suitable portion of the permeable shell **40**. Energy forms may also be applied through the delivery apparatus **110** and/or a separate catheter to facilitate fixation and/or healing of the device **10** adjacent the vascular defect **160** for some embodiments. One or more embolic devices or embolic material **176** may also optionally be delivered into the vascular defect **160** adjacent permeable shell portion that spans the neck or opening **190** of the vascular defect **160** after the device **10** has been deployed. For some embodiments, a stent or stent-like support device **173** may be implanted or deployed in a parent vessel adjacent the defect **160** such that it spans across the vascular defect **160** prior to or after deployment of the vascular defect treatment device **10**.

In any of the above embodiments, the device **10** may have sufficient radial compliance so as to be readily retrievable or retractable into a typical microcatheter **61**. The proximal portion of the device **10**, or the device as a whole for some embodiments, may be engineered or modified by the use of reduced diameter filaments, tapered filaments, or filaments oriented for radial flexure so that the device **10** is retractable into a tube that has an internal diameter that is less than about 0.7 mm, using a retraction force less than about 2.7 Newtons (0.6 lbf) force. The force for retrieving the device **10** into a microcatheter **61** may be between about 0.8 Newtons (0.18 lbf) and about 2.25 Newtons (0.5 lbf).

Engagement of the permeable shell **40** with tissue of an inner surface of a vascular defect **160**, when in an expanded relaxed state, may be achieved by the exertion of an outward radial force against tissue of the inside surface of the cavity of the patient's vascular defect **160** as shown in FIG. **29**. A similar outward radial force may also be applied by a proximal end portion and permeable shell **40** of the device **10** so as to engage the permeable shell **40** with an inside surface or adjacent tissue of the vascular defect **160**. Such forces may be exerted in some embodiments wherein the nominal outer transverse dimension or diameter of the permeable shell **40** in the relaxed unconstrained state is larger than the nominal inner transverse dimension of the vascular defect **160** within which the device **10** is being deployed, i.e., oversizing as discussed above. The elastic resiliency of the permeable shell **40** and filaments **14** thereof may be achieved by an appropriate selection of materials, such as superelastic alloys, including nickel titanium alloys, or any other suitable material for some embodiments. The conformability of a proximal portion of the permeable shell **40** of the device **10** may be such that it will readily ovalize to adapt to the shape and size of an aneurysm neck **190**, as shown in FIGS. **20-22**, thus providing a good seal and barrier to flow around the device. Thus the device **10** may achieve a good seal, substantially preventing flow around the device without the need for fixation members that protrude into the parent vessel.

Some implanted device embodiments **10** have the ends of the filaments **14** of the permeable shell **40** disposed even with or just within a plane formed by the apices of the filaments disposed adjacent to the ends. Some embodiments of the device **10** may also include a sealing member disposed within or about a perimeter zone **198** or other suitable portion of the permeable shell **40** and be configured to facilitate the disruption of flow, a fibrotic tissue response, or physically form a seal between the permeable shell **40** and a surface of the patient's vasculature. The sealing member may comprise coatings, fibers or surface treatments as described herein. The sealing member may be in a part or all of an area of the

periphery of the device adjacent where the device contacts the wall of the aneurysm near the aneurysm neck (sealing zone **198**) as shown in FIGS. **29** and **30**. The zone may extend from about the apex of the outer proximal end radius **88** for a distance up to about 20% of the height of the expanded device **10**. The sealing zone **198** may include between about 5% and 30% of the device **10** surface area. Since the flow of blood into an aneurysm **160** generally favors one side of the opening, the sealing member may be incorporated in or attached to the permeable shell **40** structure throughout the peripheral area (sealing zone **198**) shown in FIG. **30**. Some embodiments of the sealing member may include a swellable polymer. In some embodiments, the sealing member may include or bioactive material or agent such as a biologic material or biodegradable, bioresorbable or other bioactive polymer or copolymers thereof.

Any embodiment of devices for treatment of a patient's vasculature **10**, delivery system **112** for such devices **10** or both discussed herein may be adapted to deliver energy to the device for treatment of a patient's vasculature or to tissue surrounding the device **10** at the implant site for the purpose of facilitating fixation of a device **10**, healing of tissue adjacent the device or both. In some embodiments, energy may be delivered through a delivery system **112** to the device **10** for treatment of a patient's vasculature such that the device **10** is heated. In some embodiments, energy may be delivered via a separate elongate instrument (e.g. catheter, not shown) to the device **10** for treatment of a patient's vasculature and/or surrounding tissue at the site of the implant **154**. Examples of energy embodiments that may be delivered include but are not limited to light energy, thermal or vibration energy, electromagnetic energy, radio frequency energy and ultrasonic energy. For some embodiments, energy delivered to the device **10** may trigger the release of chemical or biologic agents to promote fixation of a device for treatment of a patient's vasculature **10** to a patient's tissue, healing of tissue disposed adjacent such a device **10** or both.

The permeable shell **40** of some device embodiments **10** may also be configured to react to the delivery of energy to effect a change in the mechanical or structural characteristics, deliver drugs or other bioactive agents or transfer heat to the surrounding tissue. For example, some device embodiments **10** may be made softer or more rigid from the use of materials that change properties when exposed to electromagnetic energy (e.g. heat, light, or radio frequency energy). In some cases, the permeable shell **40** may include a polymer that reacts in response to physiologic fluids by expanding. An exemplary material is described by Cox in U.S. Patent Publication No. 2004/0186562, filed Jan. 22, 2004, titled "Aneurysm Treatment Device and Method of Use", which is incorporated by reference herein in its entirety.

Device embodiments **10** and components thereof discussed herein may take on a large variety of configurations to achieve specific or generally desirable clinical results. In some device embodiments **10**, the start of the braided structure of the permeable shell **40** may be delayed from the proximal hub **68** so that the filaments **14** emanate from the proximal hub **68** in a spoke-like radial fashion as shown in the proximal end view of a device in FIG. **31**. A flattened analog version of the braid pattern of FIG. **31** is also shown in FIG. **33**. This configuration may result in a smaller width gap between the filaments **14** at a given radial distance from the proximal hub **68** relative to a fully braided configuration, the flattened analog pattern of which is shown in FIG. **34**. This may provide better flow disruption and promote hemostasis in the area of the device **10** that may be subjected to the highest

flow rates. FIG. 32 illustrates a flattened analog representation of a non-braided filament structure for reference.

The woven structure may include a portion where the weave or braid of the filaments 14 is interrupted as shown in a flat pattern analog pattern in FIG. 35. In the interrupted region, the filaments 14 may be substantially parallel to each other. The interrupted area may provide a region with different mechanical characteristics such as radial stiffness and/or compliance. Further, the interrupted region may allow for the addition of non-structural fibers or sealing members 200 as described herein or other elements to facilitate fixation, healing, fibrosis or thrombosis. The interrupted region may be within, part of or adjacent to the sealing member zone 198 as shown in FIGS. 29 and 30. The interrupted region may be less than about 50% of the surface area and may be between about 5% and 25% of the surface area.

In some embodiments, filamentary or fibrous members that are substantially non-structural may be attached or interwoven into the structural filaments of a portion of the permeable shell to increase a resistance to the flow of blood through the permeable shell structure 40. In some embodiments, a plurality of fibers 200 may be attached on the inner surface of the permeable shell 40 near the proximal hub 68 as shown in FIG. 36. The fibrous members 200 may be the fibers that form the detachment system tether for some embodiments. In some embodiments, one or more fibers 200 may be interwoven into the permeable shell filaments 14 as shown in FIG. 37. The non-structural fibers 200, which may be microfibers or any other suitable fibers, may be polymeric. The non-structural fibers 200 may include, but not limited to, any of the fibers or microfibers discussed or incorporated herein.

In some cases, device embodiments for treatment of a patient's vasculature 10 may generally be fabricated by braiding a substantially tubular braided structure with filamentary elements 14, forming the braided tubular structure into a desired shape, and heat setting the braided formed filaments into the desired shape. Once so formed, the ends of the elongate resilient filaments 14 may then be secured together relative to each other by any of the methods discussed above and proximal and distal hubs 66 and 68 added.

Such a braiding process may be carried out by automated machine fabrication or may also be performed by hand. An embodiment of a process for braiding a tubular braided structure by a manual process is shown in FIG. 38. A plurality of elongate resilient filaments 14 are secured at one end of an elongate cylindrical braiding mandrel 202 by a constraining band 204. The band 204 may include any suitable structure that secured the ends of the filaments 14 relative to the mandrel 202 such as a band of adhesive tape, an elastic band, an annular clamp or the like. The loose ends of the filaments 14 opposite the secured ends are being manipulated in a braided or woven pattern as indicated by the arrows 206 to achieve a one over-one under braid pattern for generation of a braided tubular member 208. As discussed above, although a one over-one under simple braid pattern is shown and discussed, other braid or weave patterns may also be used. One such example of another braid configuration may include a two over-one under pattern. FIG. 39 illustrates the braided tubular member 208 taking shape and lengthening as the braiding process continues as indicated by the arrows 206 in FIG. 39. Once the braided tubular member 208 achieves sufficient length, it may be removed from the braiding mandrel 202 and positioned within a shaping fixture such as the shaping fixture embodiments shown in FIGS. 40 and 41.

FIG. 40 shows the tubular braided member 208 disposed over an internal rod mandrel 210 that extends through central lumens of an internal ball mandrel 212 and a pair of opposed

recessed end forming mandrels 214. The tubular braided member 208 is also disposed over an outer surface of the internal ball mandrel 212 and within an inner lumen of each of the end forming mandrels 214. In order to hold the braided tubular member 208 onto an outer surface contour of the internal ball mandrel 212, including the recessed ends 216 thereof, the end forming mandrels 214 are configured to be pushed against and into the recessed ends 216 of the internal ball mandrel 212 such that the inside surface of the braided tubular member 208 is held against the outer contour of the internal ball mandrel 212 and fixed in place. This entire fixture 220 with the inside surface of the braided tubular structure 208 held against the outside surface of the internal ball mandrel 212 may then be subjected to an appropriate heat treatment such that the resilient filaments 14 of the braided tubular member 208 assume or are otherwise shape-set to the outer contour of the central ball mandrel 212. In some embodiments, the filamentary elements 14 of the permeable shell 40 may be held by a fixture configured to hold the permeable shell 40 in a desired shape and heated to about 475-525 degrees C. for about 5-10 minutes to shape-set the structure.

The central ball mandrel 212 may be configured to have any desired shape so as to produce a shape set tubular braided member 208 that forms a permeable shell 40 having a desired shape and size such as the globular configuration of the device 10 of FIGS. 3-6 above, or any other suitable configuration. As such, the central ball mandrel 212 may also be a globular-shaped ball with recesses in opposing sides for the hubs 66 and 68 that is placed inside the tubular braid 208. A mold or molds that have one or more pieces that are assembled to form a cavity with the desired device shape may also be used in conjunction with or in place of the end forming mandrels 214. Once the heat set process in complete, fibers, coatings, surface treatments may be added to certain filaments, portions of filaments, or all of the permeable shell 40 structure that results. Further, for some embodiments of device processing, the permeable shell 40 may be formed as discussed above by securing proximal ends 60 and distal ends 62 of elongate filamentary elements 14, or to respective proximal and distal hubs 66 and 68.

FIG. 41 shows another embodiment of a fixture for shape setting the permeable shell 40 of a device for treatment of a patient's vasculature. The fixture embodiment 230 of FIG. 41 may be used in essentially the same manner as the fixture embodiment 220 of FIG. 40, except that instead of a central ball mandrel 212, an internal tube mandrel 232 is used in conjunction with an external tube restraint 234 in order to hold the shape of the braided tubular member 208 during the heat setting process. More specifically, the tubular braided member 208 is disposed over an internal rod mandrel 210 that extends through central lumens of the internal tube mandrel 232 and a pair of opposed recessed end forming mandrels 214. The tubular braided member 208 is also disposed over an outer surface of the internal tube mandrel 232 and within an inner lumen of each of the end forming mandrels 214.

In order to hold the braided tubular member 208 into a desired shape, including the recessed ends thereof, the end forming mandrels 214 are configured to be pushed against and into recessed ends 238 of the internal tube mandrel 232 such that the inside surface of the braided tubular member 208 is held against the outer contour of the internal tube mandrel 232 and fixed in place at the ends of the tube mandrel 232. Between the ends of the tube mandrel 232, the braided tubular member 208 radially expands outwardly until it touches and is radially constrained by an inside surface of an external tube mandrel 234. The combination of axial restraint and secure-

ment of the braided tubular member **208** at the ends of the internal tube mandrel **232** in conjunction with the inward radial restraint on an outside surface of the braided tubular member **208** disposed between the proximal and distal ends thereof, may be configured to produce a desired globular configuration suitable for the permeable shell **40** of the device **10**.

Once again, this entire fixture **230** with the inside surface of the ends of the braided tubular structure **208** held against the outside surface of the ends of the internal tube mandrel **232** and an outside surface of the braided tubular member **208** radially constrained by an inside surface **233** of the external tube member **234**, may then be subjected to an appropriate heat treatment. The heat treatment may be configured such that the resilient filaments **14** of the braided tubular member **208** assume or are otherwise shape-set to the globular contour of the filaments **14** generated by the fixture **230**. In some embodiments, the filamentary elements **14** of the permeable shell **40** may be held by a fixture configured to hold the braided tubular member **208** in a desired shape and heated to about 475-525 degrees C. for about 5-10 minutes to shape-set the structure. The internal tube mandrel **232** and inside surface **233** of the external tube member **234** may be so configured to have any desired shape so as to produce a shape set tubular braided member **208** that forms a permeable shell **40** having a desired shape and size such as the globular configuration of the device of FIGS. 3-6 above, or any other suitable configuration.

For some embodiments, material may be attached to filaments **14** of the permeable shell **40** of a device **10** such that it substantially reduces the size of the fenestrations, cells or pores **64** between filaments **14** and thus reduces the porosity in that area. For example, coating embodiments may be disposed on portions of the filaments **14** to create small fenestrations or cells and thus higher density of the permeable shell **40**. Active materials such as a responsive hydrogel may be attached or otherwise incorporated into permeable shell **40** of some embodiments such that it swells upon contact with liquids over time to reduce the porosity of the permeable shell **40**.

Device embodiments **10** discussed herein may be coated with various polymers to enhance its performance, fixation and/or biocompatibility. In addition, device embodiments **10** may be made of various biomaterials known in the art of implant devices including but not limited to polymers, metals, biological materials and composites thereof. Device embodiments discussed herein may include cells and/or other biologic material to promote healing. Device embodiments discussed herein may also be constructed to provide the elution or delivery of one or more beneficial drugs, other bioactive substances or both into the blood or the surrounding tissue.

Permeable shell embodiments **40** of devices for treatment of a patient's vasculature **10** may include multiple layers. A first or outer layer may be constructed from a material with low bioactivity and hemocompatibility so as to minimize platelet aggregation or attachment and thus the propensity to form clot and thrombus. Optionally, an outer layer may be coated or incorporate an antithrombogenic agent such as heparin or other antithrombogenic agents described herein or known in the art. One or more inner layers disposed towards the vascular defect in a deployed state relative to the first layer may be constructed of materials that have greater bioactivity and/or promote clotting and thus enhance the formation of an occlusive mass of clot and device within the vascular defect. Some materials that have been shown to have bioactivity and/or promote clotting include silk, polylactic acid (PLA), polyglycolic acid (PGA), collagen, alginate, fibrin, fibrino-

gen, fibronectin, Methylcellulose, gelatin, Small Intestinal Submucosa (SIS), poly-N-acetylglucosamine and copolymers or composites thereof.

Bioactive agents suitable for use in the embodiments discussed herein may include those having a specific action within the body as well as those having nonspecific actions. Specific action agents are typically proteinaceous, including thrombogenic types and/or forms of collagen, thrombin and fibrogen (each of which may provide an optimal combination of activity and cost), as well as elastin and von Willebrand factor (which may tend to be less active and/or expensive agents), and active portions and domains of each of these agents. Thrombogenic proteins typically act by means of a specific interaction with either platelets or enzymes that participate in a cascade of events leading eventually to clot formation. Agents having nonspecific thrombogenic action are generally positively charged molecules, e.g., polymeric molecules such as chitosan, polylysine, poly(ethylenimine) or acrylics polymerized from acrylimide or methacrylamide which incorporate positively-charged groups in the form of primary, secondary, or tertiary amines or quarternary salts, or non-polymeric agents such as (tridodecylmethylammonium chloride). Positively charged hemostatic agents promote clot formation by a non-specific mechanism, which includes the physical adsorption of platelets via ionic interactions between the negative charges on the surfaces of the platelets and the positive charges of the agents themselves.

Device embodiments **10** herein may include a surface treatment or coating on a portion, side or all surfaces that promotes or inhibits thrombosis, clotting, healing or other embolization performance measure. The surface treatment or coating may be a synthetic, biologic or combination thereof. For some embodiments, at least a portion of an inner surface of the permeable shell **40** may have a surface treatment or coating made of a biodegradable or bioresorbable material such as a polylactide, polyglycolide or a copolymer thereof. Another surface treatment or coating material which may enhance the embolization performance of a device includes a polysaccharide such as an alginate based material. Some coating embodiments may include extracellular matrix proteins such as ECM proteins. One example of such a coating may be Finale Prohealing coating which is commercially available from Surmodics Inc., Eden Prairie, Minn. Another exemplary coating may be Polyzene-F which is commercially available from Celonovo BioSciences, Inc., Newnan, Ga. In some embodiments, the coatings may be applied with a thickness that is less than about 25% of a transverse dimension of the filaments **14**.

Antiplatelet agents may include aspirin, glycoprotein IIb/IIIa receptor inhibitors (including, abciximab, eptifibatide, tirofiban, lamifiban, fradafiban, cromafiban, toxfiban, XV454, lefradafiban, klerval, lotrafiban, orbofiban, and xemilofiban), dipyridamole, apo-dipyridamole, persantine, prostacyclin, ticlopidine, clopidogrel, cromafiban, cilostazol, and nitric oxide. To deliver nitric oxide, device embodiments may include a polymer that releases nitric oxide. Device embodiments **10** may also deliver or include an anticoagulant such as heparin, low molecular weight heparin, hirudin, warfarin, bivalirudin, hirudin, argatroban, forskolin, ximelagatran, vapirost, prostacyclin and prostacyclin analogues, dextran, synthetic antithrombin, Vasoflux, argatroban, efegatran, tick anticoagulant peptide, Ppack, HMG-CoA reductase inhibitors, and thromboxane A2 receptor inhibitors.

In some embodiments, the permeable shell **40** of a device **10** may be coated with a composition that may include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides). The peptides may have with alternating

31

hydrophilic and hydrophobic monomers that allow them to self-assemble under physiological conditions. The composition may comprise a sequence of amino acid residues. In some embodiments, the permeable shell may include a thin metallic film material. The thin film metal may be fabricated by sputter deposition and may be formed in multiple layers. The thin film may be a nickel-titanium alloy also known as nitinol.

In some instances, saccular aneurysms may have a generally circular flow dynamic **302** of blood as shown in FIG. **42**. While the shell slows flow into the aneurysm **300**, thrombosis and embolization may be further enhanced by an internal porous structure. In particular, a structure that is formed so that the circular flow **302**, and in particular the highest velocity region is forced to pass through one or more porous layers may have a synergistic treatment effect and promote rapid thrombosis.

In some embodiments, the distal end **308** of the inner layer (or structure) **310** may terminate with a connection or hub **304** as shown in FIG. **43**. With an internal termination of the inner structure **310**, the potential problem of length matching and buckling may be minimized due to the ability of the inner layer **310** to collapse without affecting, or minimally affecting, the outer layer **312**. In some embodiments, the collapsed length of the inner layer or structure **310** may be less than about 80% of the collapsed length of the outer layer or structure **312**. A proximal hub **314** is also shown for terminating the proximal end **316** of the outer layer **312** and the proximal end **318** of the inner layer **310**.

In some embodiments, features of which are shown in FIG. **44**, the outer structure **320** may have a truncated sphere or generally heart-like cross-sectional shape. The proximal portion **322** may be generally convex or semi-circular. These features allow the device to be placed into a saccular vascular site such as a cerebral aneurysm at an angled orientation relative to an axis **326** of the aneurysm as shown in FIG. **45**. The semi-circular proximal surface presents a relatively constant shape to the parent vessel irrespective of the angulation of the device axis **324**.

In some embodiments, the inner structure may be formed such that at least about 80% of the volume of the inner structure **328** is contained within the lower or more proximal half of the outer structure or shell volume. For some embodiments, the mesh density of the inner structure may be higher than a density of the mesh structure of the outer shell or structure. In some embodiments, the inner structure may be substantially within the proximal or lower 80% **330** of the outer shell internal volume as shown in FIG. **46**.

The inner structure **328** may be formed by braiding, weaving, or other filament interlacing techniques described herein similar to that used for formation of the shell or those techniques known in the art of medical textiles and intravascular implants. Alternatively, it may be merely twisted or allowed to form a random mesh of filaments. It may be heat set as described herein and similar to that used to form the shell or it may not be heat treated beyond any heat setting done when the filaments are formed. The inner structure filaments may be metals, polymers or composites thereof. In some embodiments, the filaments are formed of materials that can withstand heat treatment of at least about 450° C. In some embodiments, some of the filaments may be formed of an aramide fiber such as poly paraphenylene terephthalamide available under the trade name Kevlar. In some embodiments, the inner structure filamentary members may be wires with a diameter between about 10 microns (0.0004 inches) and about 30 microns (0.0012 inches). The inner structure may comprise materials, coatings or be impregnated with particles or mol-

32

ecules that release elements or chemicals that promote thrombosis and thrombus formation.

The inner structure occupying the lower portion of the outer shell may provide rapid progression of thrombosis particularly in the distal portion of an aneurysm. In some embodiments, this configuration may provide protection of the distal “dome” portion of an aneurysm where it is generally thought to be the weakest and most prone to rupture. Thus, embodiments with proximal inner structures may provide a method of rapidly occluding a distal portion of an aneurysm that is visible under angiography. An embodiment of this process is illustrated in the angiographic images, shown in FIGS. **47** and **48** of a model aneurysm created in an animal for purpose of evaluating a device embodiment. FIG. **47** is the pre-treatment angiogram of an aneurysm created in an animal model prior to treatment with an embodiment of a device for treatment of a patient’s vasculature having some similarity in structure to the device embodiment shown in FIG. **43**. FIG. **48** is representative of an angiogram ten (10) minutes post treatment with the device for treatment of a patient’s vasculature showing rapid occlusion of the distal portion of the aneurysm.

Generally speaking, one or more of the features, dimensions or materials of the various device embodiments discussed herein may be used in other similar device embodiments discussed herein, as well as with other device embodiments. For example, any suitable feature, dimension or material discussed here may also be applied to device embodiments such as those discussed in commonly owned U.S. Patent Publication No. 2011/0022149, published Jan. 27, 2011, titled “Methods and Devices for Treatment of Vascular Defects”, U.S. Patent Publication No. 2009/0275974, published Nov. 5, 2009, titled “Filamentary Devices for Treatment of Vascular Defects”, U.S. Patent Publication No. 2011/0152993, published Jun. 23, 2011, titled “Multiple Layer Filamentary Devices for Treatment of Vascular Defects” and U.S. Publication No. 2012/0283768, published Nov. 8, 2012, titled “Method and Apparatus for the Treatment of Large and Giant Vascular Defects”, all of which are incorporated by reference herein in their entirety.

In any of the device embodiments discussed or incorporated herein for treatment of a patient’s vascular defect or aneurysm, the device may comprise one or more composite filaments. A composite filament (e.g. wires) may be defined as a filament that comprises a plurality of materials in either a mixture or alloy or in a composite structure where two materials are physically combined into one. The addition of at least some composite wires into the device may provide improved visibility of the device under external imaging such as x-ray, fluoroscopy, magnetic resonance imaging and the like. In some embodiments, composite wires may provide improved mechanical characteristics.

For some composite filament embodiments, the composite filaments may be disposed in a coaxial arrangement with one material substantially inside the other as shown in FIG. **49**. One known method of fabrication of such as coaxial composite wire is a drawn filled tube wire wherein the materials of the drawn filled tube are combined but retain their individual mechanical properties. Drawn filled tube wires are commercially available from Ft. Wayne Metals, Ft. Wayne, Ind. In some cases, the process for producing drawn filled tube filaments may include extreme compressive forces such that the mechanical bond between an outer surface **334** of the internal fill wire **332** and an internal surface **338** of the external tube **336** is metallurgically sound. In some instances, a plurality of external tubes, each of a different material, may be layered over the internal wire and each other in order to combine the mechanical properties of the plurality of materials. For such

embodiments, the drawn filled tube filament may include 2, 3, 4, 5 or more external tube layers. In some embodiments, the drawn filled tube wires are formed of a combination of an external nitinol (NiTi) tube and a highly radiopaque fill wire which may be concentrically disposed within the external tube. Various radiopaque materials and metals known in the art may be used as the fill wire including but not limited to gold, platinum, tantalum and the like. One advantage of a composite with a NiTi exterior and internal highly radiopaque fill wire is that the device can substantially maintain its highly elastic or superelastic behavior and the majority of the blood contacting surfaces remain nitinol. This allows for a device with substantially improved visibility under x-ray imaging while maintaining the proper range of mechanical characteristics.

In some cases, the specific construction of a drawn filled tube wire or filament may be important in order to maintain desired performance characteristics of a device for treatment of a vascular defect. More specifically, it may be important to balance the stiffness, elasticity and radiopacity of the composition. In particular, for drawn filled tube filament embodiments that include an internal wire **332** of ductile radiopaque material such as platinum and an outer tube **336** of an elastic or superelastic material such as NiTi, it can be necessary to carefully balance the ratio of the percent cross sectional area of the internal wire with regard to the overall cross sectional area of the filament. Such a ratio may be referred to as a fill ratio. If an embodiment includes too little radiopaque or highly radiopaque internal tube material relative to the external tube material, there may not be sufficient radiopacity and visibility. On the other hand, if an embodiment includes too much internal wire material with respect to the elastic external tube, the mechanical properties of the ductile radiopaque material may overwhelm the elastic properties of the outer tube material and the filaments may be prone to taking a set after compression etc. resulting in permanent deformation. For some embodiments, a desired composite or drawn filled tube wire may be constructed with a fill ratio of cross sectional area of internal fill wire to cross sectional area of the entire composite filament of between about 10% and about 50%, more specifically between about 20% and about 40%, and even more specifically, between about 25% and about 35%.

In some embodiments, the number of composite wires may be between about 40 and 190, and between about 50 and 190 in other embodiments, and between about 70 and 150 in other embodiments. In some embodiments, the devices for treatment of a patient's vasculature may have at least about 25% composite wires relative to the total number of wires and in some embodiments such devices may have at least about 40% composite wires relative to a total number of wires in the device. For example, a first subset of elongate resilient filaments may comprise filaments, each having a composite of highly radiopaque material and a high strength material, and a second subset of elongate resilient filaments may consist essentially of a high strength material. For example, the highly radiopaque material may comprise platinum, platinum alloy such as 90% platinum/10% iridium, or gold or tantalum. The high strength material may comprise NiTi. While composite wires may provide enhanced visualization and/or mechanical characteristics, they may in some configurations have reduced tensile strength in comparison to NiTi wires of a similar diameter. In other configurations, depending on their diameter, the composite wires may increase the collapsed profile of the devices. Therefore, it may be beneficial to minimize the number. Lower percentages of composite wires may not be sufficiently visible with current imaging equipment

particularly in neurovascular applications where the imaging is done through the skull. In addition, too many composite wires (or composite wires with extremely high fill ratios) may result in devices with excessive artifact on CT or MRI imaging. The described ratios and amounts of highly radiopaque material provide a unique situation for neurovascular implants where the periphery of the device is just visible under transcranial fluoroscopy but the device imaged area is not completely obliterated (i.e. due to artifact) as it is with conventional embolic coils that are made substantially out of platinum or platinum alloys.

One manner of achieving the desired degree of radiopacity is by selecting a particular combination of fill ratio of the composite wires and the percent of composite wires in relation to the total number of wires. Devices according to embodiments having a single layer braided (woven) structure were constructed. For example, an embodiment of a braided structure comprising 72 composite Platinum/NiTi drawn filled tube wires having a 0.00075" diameter and a platinum fill ratio of 30% and 72 NiTi wires having a 0.00075" diameter was constructed. The total percent of platinum (by total % cross sectional area) in the braided structure was about 15%. Another embodiment of a braided structure comprising 108 composite Platinum/NiTi drawn filled tube wires having a 0.001" diameter and a platinum fill ratio of 30% and 72 NiTi wires having a 0.00075" diameter was constructed. The total percent of platinum in the braided structure was about 22%. Still another embodiment of a braided structure comprising 72 composite Platinum/NiTi drawn filled tube wires having a 0.00125" diameter and a platinum fill ratio of 30% and 108 NiTi wires having a 0.00075" diameter was constructed. The total percent of platinum in the braided structure was about 19.5%. Yet another embodiment of a braided structure comprising 108 composite Platinum/NiTi drawn filled tube wires having a 0.00125" diameter and a platinum fill ratio of 30% and 108 NiTi wires having a 0.00075" diameter was constructed. The total percent of platinum in the braided structure was about 22%. Devices constructed according to each of these embodiments were each implanted into living bodies and imaged using fluoroscopy. In each case, the periphery of the device was visible under transcranial fluoroscopy but the device imaged area was not completely obliterated (i.e. due to artifact).

Additionally, devices according to embodiments having an outer braided (woven) structure and an inner braided (woven) structure (as in FIGS. **43-46**) were constructed. For example, an embodiment having a braided outer structure comprising 54 composite Platinum/NiTi drawn filled tube wires having a 0.001" diameter and a platinum fill ratio of 30% and 54 NiTi wires having a 0.00075" diameter, and having a braided inner structure comprising 108 NiTi wires having a 0.00075" diameter was constructed. The total percent of platinum in the braided outer structure was about 19%. The total percent of platinum in the combined outer structure and inner structure was about 11%. Still another embodiment having a braided outer structure comprising 48 composite Platinum/NiTi drawn filled tube wires having a 0.001" diameter and a platinum fill ratio of 30% and 96 composite Platinum/NiTi drawn filled tube wires having a 0.0015" diameter and a platinum fill ratio of 30%, and having a braided inner structure comprising 132 NiTi wires having a 0.00075" diameter and 12 NiTi wires having a 0.001" diameter was constructed. The total percent of platinum in the braided outer structure was about 30%. The total percent of platinum in the combined outer structure and inner structure was about 18.5%. Devices constructed according to each of these embodiments were each implanted into living bodies and imaged using fluoroscopy. In each case,

the periphery of the device was visible under transcranial fluoroscopy but the device imaged area was not completely obliterated (i.e. due to artifact).

In some embodiments the total cross sectional area of the highly radiopaque material is between about 11% and about 30% of the total cross sectional area of the plurality of elongate elements. In some embodiments the total cross sectional area of the highly radiopaque material is between about 15% and about 30% of the total cross sectional area of the plurality of elongate elements. In some embodiments the total cross sectional area of the highly radiopaque material is between about 19% and about 30% of the total cross sectional area of the plurality of elongate elements. In some embodiments the total cross sectional area of the highly radiopaque material is between about 11% and about 18.5% of the total cross sectional area of the plurality of elongate elements.

Because the radiopacity of the composite filaments comprising a highly radiopaque material can allow sufficient device visualization (e.g. on fluoroscopy), it may be desired to make one or more of the hubs **304**, **306**, **314** from less radiopaque or non-radiopaque materials. In some embodiments, platinum, platinum alloy (e.g. 90% Platinum/10% Iridium), may not be desired, if their radiopacity would overpower the radiopacity of the composite filaments, and thus, make their delineation difficult. The use of less radiopaque or non-radiopaque materials to make the hubs **304**, **306**, **314** may thus be desired in these embodiments, but can also be used on the hubs **66**, **68** of other embodiments. One or more titanium or titanium alloy hubs or NiTi hubs may be used in place of highly radiopaque hubs. The use of titanium, titanium alloy, or NiTi hubs may also aid in welding to NiTi filaments, as their melt temperatures are more closely matched than if, for example, platinum, platinum alloy, or gold hubs were being used. The result can be a joint between the filaments and the hub that has a higher tensile breakage force. Joints of this variety were constructed and demonstrated an approximately 48% improvement in tensile force.

An embodiment of a mesh (e.g. braided) device **400** having a substantially spherical expanded configuration and a substantially closed distal apex **415** is illustrated in FIG. **50** in its expanded configuration. The mesh device **400** has a first braided portion **402** having a first average braid material density  $BD_{avg1}$  and a second portion **404** having a second average braid material density  $BD_{avg2}$ . The second average braid material density  $BD_{avg2}$  may be braided with tighter angulation to be greater than the first average braid material density  $BD_{avg1}$ . The braid material density  $BD$  may transition from the first braided portion **402** to the second braided portion **404** over a transition zone **TZ 406**. Alternatively, both average braid material densities  $BD_{avg1}$ ,  $BD_{avg2}$  may be made the same.

The mesh device **400** has a proximal end **408** and a distal end **410**, the first braided portion **402** adjacent the distal end **410** and the second braided portion **404** adjacent the proximal end **408**. Individual filaments **412** from which the mesh device **400** is braided can be secured together at the proximal end **408** by a marker band **414**, for example, a marker band comprising a highly radiopaque material such as platinum, a platinum alloy, or gold, or a marker band comprising a less radiopaque or non-radiopaque material, such as titanium, titanium alloy, or NiTi. Alternatively, the individual filaments **412** may be held together by welding, adhesives, expoxies or any other joining method. The adhesive or epoxy may be doped with radiopaque material, such as tantalum, in order to

increase visualization. The mesh device **400**, when used for the purpose of treating a vascular defect such as a cerebral aneurysm, may be placed into the aneurysm so that the second braided portion **404** covers the neck of the aneurysm. The second average braid material density  $BD_{avg2}$  of the second braided portion **404** can be made to be above an average braid material density  $BD_{avg}$  that is in a range that effectively stag-nates the flow of blood into the aneurysm when the mesh device **400** is expanded within the aneurysm.

A castellated mandrel assembly **420** for forming the substantially closed distal apex **415** of the mesh device **400** is shown in FIG. **51**. The castellated mandrel assembly **420** comprises a castellated mandrel **422** having a radiused cap **424** within its central cavity **426**. The castellated mandrel **422** includes a cylindrical battlement-like structure **428** having a plurality of slots, or crenels **430**, separated by a plurality of posts, or merlons **432**. The embodiment of FIG. **51** comprises 18 crenels **430** and 18 merlons **432**, however, alternative embodiments may include 27 crenels **430** and 27 merlons **432**, or other quantities. The radiused cap **424** has a convex radius whose surface is contained within the portion of the central cavity **426** surrounded by the battlement-like structure **428**. The radiused cap **424** may be made from a separate structure than the castellated mandrel **422** and may, for example, comprise a pin which inserts into a central cavity in the castellated mandrel **422** for securement purposes. Alternatively, this may be a threaded union, or they may be attached with adhesive, epoxy, welding, or other joining method. The radiused cap **424** and the castellated mandrel **422** may be made from rigid, durable materials, such as stainless steel.

The loading of the castellated mandrel assembly **420** during the process of constructing the mesh device **400** of FIG. **50** is shown in FIGS. **51** and **52**. Merlons **432a-r** are circum-ferentially arrayed around the battlement-like structure **428**, with crenels **430a-r** between each of the merlons **432a-r**. A first filament **434a** is loaded in a downward direction into crenel **430a** (between merlons **432r** and **432a**) and crenel **430j** (between merlons **432i** and **432j**) and secured to the castellated mandrel assembly **420**. The first filament **434a** may be secured, for example, so that a central portion **436a** of the first filament **434a** is held snugly across the surface of the convex radius of the radiused cap **424**. In an 18-crenel embodiment of the castellated mandrel assembly **420**, the locations of crenels **430a** and **430j** are 180° from each other, approximating, for example, 12 o'clock and 6 o'clock locations on a clock face. Alternatively, other non-180° configurations may be used which create a hole instead of the substantially closed distal apex **415** of the mesh device **400**. Continuing with the loading of filaments in the 180° configuration, a second filament **434b** is loaded in a downward direction into crenel **430b** (between merlons **432a** and **432b**) and crenel **430k** (between merlons **432j** and **432k**) and secured to the castellated mandrel assembly **420**. A central portion **436b** of the second filament **434b** is crossed over the central portion **436a** of the first filament **434a**, and held snugly across the convex radius of the radiused cap **424**. This loading is continued until all filaments **434** are loaded and secured to the castellated mandrel assembly **420**. Multiple filaments **434** may be loaded into each of the crenels **430**, or only certain selected crenels **430**. After loading all of the filaments **434** into the crenels **430** and securing the filaments **434** to the castellated mandrel assembly **420**, the filaments **434** are ordered and extended radially, and the tubular braiding process is performed. The resulting mesh device of FIG. **50** has a substantially closed apex **415**, because of the manner in which the filaments **434** are layered over each other at the

radiused cap 424. The mesh device 400 of FIG. 50 may be made with, for example, 40 to 216 filaments 434, but because the loading of the mandrel produces the equivalent of two filaments 434 from a single piece of wire, there are only 20 to 108 pieces of wire required. The mesh device may have only the single marker band 414, as no securing of wires is needed at the distal end 410. A mixture of composite filaments and NiTi filaments may be chosen in order to achieve the desired amount of radiopacity of the entire mesh device 400. The substantially closed apex 415, though not having a marker band, can still maintain sufficient radiopacity from the radiopacity of the composite filaments alone.

FIG. 52 illustrates a top view of the loaded castellated mandrel assembly 420 of the mesh device 400, made in conjunction with the method described. Because each of the filaments 434 crosses a center crossing point 438, the substantially closed distal apex 415 of the mesh device 400 (FIG. 50) includes many layers of filaments 434 at this center crossing point 438. However, shaping and heat forming of the mesh device 400 can at least partially reform some or all of the filaments 434 at the center at the center crossing point 438, spreading them out in order to lessen the bulk at the center crossing point 438.

In some embodiments, composite filaments or wires may be made, at least in part from various single and multi-layered, coiled or braided configurations. One potentially suitable component is called a Helical Hollow Strand and is commercially available from Ft. Wayne Metals, Ft. Wayne, Ind. Another potential construction is commercially available from Heraeus Medical Components.

One embodiment of a device for treatment of a patient's vasculature may include a self-expanding resilient permeable structure having a proximal end, a distal end, a longitudinal axis, a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state and extending from the longitudinal axis between the proximal end and the distal end, a plurality of elongate resilient filaments secured relative to each other at at least one of the proximal end or distal end, wherein the elongate resilient filaments include a first subset of elongate resilient filaments, each of the first subset of filaments including a composite of a highly radiopaque material and a high strength material, and each of a second subset of elongate resilient filaments essentially of a high strength material, wherein the first subset of filaments is about 25% to about 40% of the total number of the plurality of elongate resilient filaments. In a particular embodiment, the high strength material of the elongate resilient filaments of the first subset of filaments and the high strength material of the elongate resilient filaments of the second subset of filaments comprise a superelastic material, for example NiTi. In one embodiment, the first subset of elongate resilient filaments may comprise about 50 to about 190 filaments. In one embodiment, the first subset of elongate resilient filaments may comprise about 70 to about 150 filaments. In one embodiment, the elongate resilient filaments may comprise drawn filled tube wires. In one embodiment, drawn filled tube wires may have a cross-sectional fill area ratio of between about 10% and about 50%. In one embodiment, drawn filled tube wires may have a cross-sectional fill area ratio of between about 20% and about 40%. In one embodiment, drawn filled tube wires may have a cross-sectional fill area ratio of between about 25% and about 35%. In one embodiment, the highly radiopaque material may include tantalum.

In one embodiment, the highly radiopaque material may include platinum. In one embodiment, the highly radiopaque material may include gold.

One embodiment of a device for treatment of a patient's vasculature may include a self-expanding resilient permeable structure having a proximal end, a distal end, a longitudinal axis, a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state and extending from the longitudinal axis between the proximal end and the distal end, a plurality of elongate resilient filaments secured relative to each other at at least one of the proximal end or distal end, wherein the elongate resilient filaments include a first subset of elongate resilient filaments, each of the first subset of filaments including a composite of a highly radiopaque material and a high strength material, and each of a second subset of elongate resilient filaments essentially of a high strength material, wherein the first subset of filaments is at least about 25% of the total number of the plurality of elongate resilient filaments. In a particular embodiment, the high strength material of the elongate resilient filaments of the first subset of filaments and the high strength material of the elongate resilient filaments of the second subset of filaments comprise a superelastic material, for example NiTi. In one embodiment, the first subset of filaments is at least 40% of the total number of the plurality of elongate resilient filaments. In one embodiment, the first subset of elongate resilient filaments may comprise about 50 to about 190 filaments. In one embodiment, the first subset of elongate resilient filaments may comprise about 70 to about 150 filaments. In one embodiment, the elongate resilient filaments may comprise drawn filled tube wires. In one embodiment, drawn filled tube wires may have a cross-sectional fill area ratio of between about 10% and about 50%. In one embodiment, drawn filled tube wires may have a cross-sectional fill area ratio of between about 20% and about 40%. In one embodiment, drawn filled tube wires may have a cross-sectional fill area ratio of between about 25% and about 35%. In one embodiment, the highly radiopaque material may include tantalum. In one embodiment, the highly radiopaque material may include platinum. In one embodiment, the highly radiopaque material may include gold.

One embodiment of a device for treatment of a patient's vasculature may include a self-expanding resilient permeable shell having a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together, which define a cavity of the permeable shell and which include at least about 40% composite filaments relative to a total number of filaments, the composite filaments including a high strength material and a highly radiopaque material. In one embodiment, the plurality of elongate filaments may be secured relative to each other at a distal end of the permeable shell. In one embodiment, the plurality of elongate filaments may be secured relative to each other at a proximal end of the permeable shell. In one embodiment, the plurality of elongate filaments may include about 50 to about 190 composite filaments. In one embodiment, the plurality of elongate filaments may include about 70 to about 150 composite filaments. In one embodiment, the composite filaments may be drawn filled tubes. In one embodiment, drawn filled tube wires may have a fill ratio of cross sectional area of between about 10% and about 50%. In one embodiment, drawn filled tube wires may have a fill ratio of cross sectional area of between about 20% and about 40%. In one embodiment, drawn filled tube wires may have a



fill ratio of cross sectional area of between about 25% and about 35%. In one embodiment, the highly radiopaque material may include tantalum. In one embodiment, the highly radiopaque material may include platinum. In one embodiment, the highly radiopaque material may include gold.

One embodiment of a device for treatment of a patient's vasculature may include a self-expanding resilient permeable shell having a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together, the plurality of filaments having a total cross sectional area and further defining a cavity of the permeable shell and which include at least some composite filaments, the composite filaments including a high strength material and a highly radiopaque material, and wherein the total cross sectional area of the highly radiopaque material is between about 11% and about 30% of the total cross sectional area of the plurality of elongate filaments. In one embodiment, the total cross sectional area of the highly radiopaque material is between about 15% and about 30% of the total cross sectional area of the plurality of elongate filaments. In one embodiment, the total cross sectional area of the highly radiopaque material is between about 15% and about 22% of the total cross sectional area of the plurality of elongate filaments. In one embodiment, the total cross sectional area of the highly radiopaque material is between about 19% and about 30% of the total cross sectional area of the plurality of elongate filaments. In one embodiment, the total cross sectional area of the highly radiopaque material is between about 11% and about 18.5% of the total cross sectional area of the plurality of elongate filaments. In one embodiment, the plurality of elongate filaments may be secured relative to each other at a distal end of the permeable shell. In one embodiment, the plurality of elongate filaments may be secured relative to each other at a proximal end of the permeable shell. In one embodiment, the plurality of elongate filaments may include about 50 to about 190 composite filaments. In one embodiment, the plurality of elongate filaments may include about 70 to about 150 composite filaments. In one embodiment, the composite filaments may be drawn filled tubes. In one embodiment, drawn filled tube wires may have a fill ratio of cross sectional area of between about 10% and about 50%. In one embodiment, drawn filled tube wires may have a fill ratio of cross sectional area of between about 20% and about 40%. In one embodiment, drawn filled tube wires may have a fill ratio of cross sectional area of between about 25% and about 35%. In one embodiment, the highly radiopaque material may include tantalum. In one embodiment, the highly radiopaque material may include platinum. In one embodiment, the highly radiopaque material may include gold.

With regard to the above detailed description, like reference numerals used therein refer to like elements that may have the same or similar dimensions, materials and configurations. While particular forms of embodiments have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the embodiments of the invention. Accordingly, it is not intended that the invention be limited by the foregoing detailed description.

What is claimed is:

1. A device for treatment of a patient's cerebral aneurysm, comprising:

a resilient self-expanding permeable shell including a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globu-

lar and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together and define a cavity of the permeable shell, the permeable shell comprising at least some filaments consisting of nitinol and at least some composite filaments, the composite filaments comprising drawn filled tube wires comprising an external nitinol tube and a highly radiopaque material concentrically disposed within the external tube, and wherein the permeable shell has at least about 40% composite filaments relative to a total number of filaments, and wherein a total number of filaments is about 70 to about 300.

2. The device of claim 1 wherein the plurality of elongate filaments are secured relative to each other at a distal end of the permeable shell.

3. The device of claim 1, wherein the plurality of elongate filaments are secured relative to each other at a proximal end of the permeable shell.

4. The device of claim 1, wherein the drawn filled wires have a fill ratio of cross sectional area of between about 10% and about 50%.

5. The device of claim 1, wherein the drawn filled tube wires have a fill ratio of cross sectional area of between about 20% and about 40%.

6. The device of claim 1, wherein the drawn filled tube wires have a fill ratio of cross sectional area of between about 25% and about 35%.

7. The device of claim 1, wherein the highly radiopaque material of the composite filaments comprises tantalum.

8. The device of claim 1, wherein the highly radiopaque material of the composite filaments comprises platinum.

9. The device of claim 1, wherein the highly radiopaque material of the composite filaments comprises gold.

10. The device of claim 1, wherein a ratio of a number of the at least some filaments consisting of nitinol to the number of at least some composite filaments is selected from the group consisting of 1:1, 1:1.5, and 1.5:1.

11. The device of claim 1, wherein each of the composite filaments has a diameter selected from the group consisting of 0.00075", 0.001", and 0.00125".

12. A device for treatment of a patient's cerebral aneurysm, comprising:

a resilient self-expanding permeable shell including a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together and define a cavity of the permeable shell, the plurality of filaments having a total cross sectional area, the permeable shell comprising at least some filaments consisting of nitinol and at least some composite filaments, the composite filaments comprising drawn filled tube wires comprising an external nitinol tube and a highly radiopaque material, and wherein the permeable shell has at least about 40% composite filaments relative to a total number of filaments, and wherein a total number of filaments is about 70 to about 300; and

wherein the total cross sectional area of the highly radiopaque material is between about 11% and about 30% of the total cross sectional area of the plurality of elongate elements.

13. The device of claim 12, wherein the total cross sectional area of the highly radiopaque material is between about 15% and about 30% of the total cross sectional area of the plurality of elongate elements.



41

14. The device of claim 13, wherein the total cross sectional area of the highly radiopaque material is between about 15% and about 22% of the total cross sectional area of the plurality of elongate elements.

15. The device of claim 13, wherein the total cross sectional area of the highly radiopaque material is between about 19% and about 30% of the total cross sectional area of the plurality of elongate elements.

16. The device of claim 12, wherein the total cross sectional area of the highly radiopaque material is between about 11 and about 18.5% of the total cross sectional area of the plurality of elongate elements.

17. The device of claim 12, wherein the plurality of elongate filaments are secured relative to each other at a distal end of the permeable shell.

18. The device of claim 12, wherein the plurality of elongate filaments are secured relative to each other at a proximal end of the permeable shell.

19. The device of claim 12, wherein the drawn filled tube wires have a fill ratio of cross sectional area of between about 10% and about 50%.

20. The device of claim 12, wherein the drawn filled tube wires have a fill ratio of cross sectional area of between about 20% and about 40%.

21. The device of claim 12, wherein the drawn filled tube wires have a fill ratio of cross sectional area of between about 25% and about 35%.

22. The device of claim 12, wherein the highly radiopaque material comprises tantalum.

23. The device of claim 12, wherein the highly radiopaque material comprises platinum.

24. The device of claim 12, wherein the highly radiopaque material comprises gold.

25. The device of claim 12, wherein a ratio of a number of the at least some filaments consisting of nitinol to the number of at least some composite filaments is selected from the group consisting of 1:1, 1:1.5, and 1.5:1.

26. The device of claim 12, wherein each of the composite filaments has a diameter selected from the group consisting of 0.00075", 0.001", and 0.00125".

27. A device for treatment of a patient's cerebral aneurysm, comprising:

a resilient self-expanding permeable shell including a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together and define a cavity of the permeable shell, the permeable shell comprising at least some filaments consisting of nitinol and at least some composite filaments, the composite filaments comprising drawn filled tube wires comprising an external nitinol tube and a highly radiopaque material concentrically disposed within the external tube, and wherein a total number of filaments is about 70 to about 300, and wherein the permeable shell has either at least

42

40% composite filaments or has a total number of composite filaments between about 40 and 190.

28. The device of claim 27, wherein the plurality of elongate filaments are secured relative to each other at a distal end of the permeable shell.

29. The device of claim 27, wherein the plurality of elongate filaments are secured relative to each other at a proximal end of the permeable shell.

30. The device of claim 27, wherein the highly radiopaque material of the composite filaments comprises platinum.

31. The device of claim 27, wherein a ratio of a number of the at least some filaments consisting of nitinol to the number of at least some composite filaments is selected from the group consisting of 1:1, 1:1.5, and 1.5:1.

32. The device of claim 27, wherein each of the composite filaments has a diameter selected from the group consisting of 0.00075", 0.001", and 0.00125".

33. A device for treatment of a patient's cerebral aneurysm, comprising:

a resilient self-expanding permeable shell including a radially constrained elongated state configured for delivery within a catheter lumen, an expanded state with a globular and longitudinally shortened configuration relative to the radially constrained state, and a plurality of elongate filaments which are woven together and define a cavity of the permeable shell, the plurality of filaments having a total cross sectional area, the permeable shell comprising at least some filaments consisting of nitinol and at least some composite filaments, the composite filaments comprising drawn filled tube wires comprising an external nitinol tube and a highly radiopaque material, and wherein a total number of filaments is about 70 to about 300, and wherein the permeable shell has either at least 40% composite filaments or has a total number of composite filaments between about 40 and 190; and wherein the total cross sectional area of the highly radiopaque material is between about 11% and about 30% of the total cross sectional area of the plurality of elongate elements.

34. The device of claim 33, wherein the plurality of elongate filaments are secured relative to each other at a distal end of the permeable shell.

35. The device of claim 33, wherein the plurality of elongate filaments are secured relative to each other at a proximal end of the permeable shell.

36. The device of claim 33, wherein the highly radiopaque material of the composite filaments comprises platinum.

37. The device of claim 33, wherein a ratio of a number of the at least some filaments consisting of nitinol to the number of at least some composite filaments is selected from the group consisting of 1:1, 1:1.5, and 1.5:1.

38. The device of claim 33, wherein each of the composite filaments has a diameter selected from the group consisting of 0.00075", 0.001", and 0.00125".

\* \* \* \* \*